var title_f15_37_15952="Hurler brain MRI";
var content_f15_37_15952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brain MRI in a patient with mucopolysaccharidosis type I (MPS I, Hurler syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Horizontal T2-weighted MR cranial image in a five-year-old with Hurler syndrome. The large lateral ventricles are due to severe communicating hydrocephalus with possible atrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Emil Kakkis, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15952=[""].join("\n");
var outline_f15_37_15952=null;
var title_f15_37_15953="Perforation of the distal esophagus";
var content_f15_37_15953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforation of the distal esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the exposed esophagus with a perforation in the distal third.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15953=[""].join("\n");
var outline_f15_37_15953=null;
var title_f15_37_15954="Barker method of vacuum assisted temporary abdominal closure";
var content_f15_37_15954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Barker method of vacuum assisted temporary abdominal closure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15954=[""].join("\n");
var outline_f15_37_15954=null;
var title_f15_37_15955="Interscalene block ultrasound";
var content_f15_37_15955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Interscalene block ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With an ultrasound-guided technique, the probe is placed in a transverse position just above the clavicle. The nerves of the brachial plexus appear lateral to the subclavian artery and are traced cephalad. At the C6 level, the nerves of the brachial plexus are visualized in a vertical orientation within the interscalene groove (ie, between the anterior and middle scalene muscles).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15955=[""].join("\n");
var outline_f15_37_15955=null;
var title_f15_37_15956="Acetic acid: Patient drug information";
var content_f15_37_15956=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     see \"Acetic acid: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/39/42610?source=see_link\">",
"     see \"Acetic acid: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to rinse the bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701430",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705375",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ear:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701377",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a ruptured ear drum.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear discomfort.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad ear pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705375",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ear:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what is given to you by your doctor for using the wick.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705436",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Irrigation solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694770",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. It is for use as a bladder rinse only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10937 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-DB4EA05A22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15956=[""].join("\n");
var outline_f15_37_15956=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016406\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016405\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016410\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016411\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016413\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016408\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016409\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016414\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016415\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=related_link\">",
"      Acetic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/39/42610?source=related_link\">",
"      Acetic acid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_37_15957="Encopresis diagram PI";
var content_f15_37_15957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Encopresis diagram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Encopresis (fecal incontinence) in children is when a toilet-trained child often has bowel movements in the wrong place. Constipation is the most common cause. This diagram shows how constipation can make bowel movements build up and how treatment works.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15957=[""].join("\n");
var outline_f15_37_15957=null;
var title_f15_37_15958="Sumatriptan: Patient drug information";
var content_f15_37_15958=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sumatriptan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     see \"Sumatriptan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=see_link\">",
"     see \"Sumatriptan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alsuma&trade;;",
"     </li>",
"     <li>",
"      Imitrex&reg;;",
"     </li>",
"     <li>",
"      Sumavel&reg; DosePro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sumatriptan&reg;;",
"     </li>",
"     <li>",
"      Ava-Sumatriptan;",
"     </li>",
"     <li>",
"      CO Sumatriptan;",
"     </li>",
"     <li>",
"      Dom-Sumatriptan;",
"     </li>",
"     <li>",
"      Imitrex&reg;;",
"     </li>",
"     <li>",
"      Imitrex&reg; DF;",
"     </li>",
"     <li>",
"      Imitrex&reg; Injection;",
"     </li>",
"     <li>",
"      Imitrex&reg; Nasal Spray;",
"     </li>",
"     <li>",
"      Mylan-Sumatriptan;",
"     </li>",
"     <li>",
"      PHL-Sumatriptan;",
"     </li>",
"     <li>",
"      PMS-Sumatriptan;",
"     </li>",
"     <li>",
"      Riva-Sumatriptan;",
"     </li>",
"     <li>",
"      Sandoz-Sumatriptan;",
"     </li>",
"     <li>",
"      Sumatriptan Injection;",
"     </li>",
"     <li>",
"      Sumatriptan Sun Injection;",
"     </li>",
"     <li>",
"      Sumatryx;",
"     </li>",
"     <li>",
"      Taro-Sumatriptan;",
"     </li>",
"     <li>",
"      Teva-Sumatriptan;",
"     </li>",
"     <li>",
"      Teva-Sumatriptan DF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sumatriptan succinate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703464",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Some types of migraine headaches, chest pain or pressure, diseased arteries going to the legs, heart attack, heart disease, very bad liver disease, poor bowel blood flow, stroke, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug to stop you from getting migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703841",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, or zolmitriptan in the last 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken ergotamine, methysergide, or dihydroergotamine in the last 24 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4036462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you take this drug 10 or more days in a month your headaches may become worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loss of eyesight. This can be long-lasting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral tablet/shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705434",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Intranasal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache or if headache is not better after the first dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with liquids as early as you can after the attack has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695208",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your headache comes back after the first dose, 1 more dose may be taken 2 hours after the first one.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot is given under the skin as early as it can be after the attack has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If more than 1 shot is needed, space each shot by 1 hour.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705434",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Intranasal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray a single dose in 1 nostril as early as you can after the attack has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the headache comes back, the dose may be repeated once after 2 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11064 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15958=[""].join("\n");
var outline_f15_37_15958=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224277\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021141\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021143\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021142\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021147\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021148\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021150\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021145\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021146\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021151\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021152\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=related_link\">",
"      Sumatriptan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/13/16599?source=related_link\">",
"      Sumatriptan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_37_15959="Evaluation of decreased fetal movements";
var content_f15_37_15959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of decreased fetal movements",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15959/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15959/contributors\">",
"     Ruth C Fretts, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15959/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15959/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15959/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/37/15959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perception of fetal movement typically begins in the second trimester, and occurs earlier in parous women than nulliparous women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/1\">",
"     1",
"    </a>",
"    ]. The mother's first perception of fetal movement, termed \"quickening\", is often described as a gentle flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/2\">",
"     2",
"    </a>",
"    ]. Awareness of fetal movement is a means for the mother to monitor her fetus without the need for a clinician or equipment. Maternal perception of fetal movement is reassuring to pregnant women, whereas decreased fetal movement (DFM) is a common reason for concern.",
"   </p>",
"   <p>",
"    Maternal monitoring of fetal movement is a means of screening fetal status. The rationale is based on the assumption that early recognition of decreased fetal movement (DFM) makes it possible for the clinician to intervene at a stage when the fetus is still compensated, and thus prevent progression to fetal or neonatal injury or death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL FETAL MOVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal activity can be noted sonographically as early as the first trimester and includes a wide range of movements of the trunk (eg, bending, startle, hiccup, breathing, rotation), limbs (eg, stretch, hand to face, opening and closing of hands), and face and head (eg, head rotation, suck, yawn, tongue protrusion). When correlated sonographically, one study found about 50 percent of isolated limb movements were perceived by the mother, whereas 80 percent of movements involving both the trunk and limb were perceived [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/3\">",
"     3",
"    </a>",
"    ]. In a literature review, mothers perceived 33 to 88 percent of ultrasonographically visualized fetal movements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The perceived frequency of fetal movement during fetal wakefulness in normal pregnancy is constant throughout the third trimester, although the quality of perceived movements changes. Reports of reduced activity towards term are either based upon data from high-risk pregnancies or due to counting at specific hours, and thus biased toward fetal quiet cycles, which become longer with advancing gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/5\">",
"     5",
"    </a>",
"    ]. Fetal movement increases throughout day, with peak activity late at night [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DECREASED FETAL MOVEMENT (DFM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;We base the diagnosis of DFM upon qualitative maternal perception of a reduction of fetal movement.",
"   </p>",
"   <p>",
"    There is no consensus regarding an appropriate definition of DFM since the level of fetal movement that reliably distinguishes a healthy fetus from a fetus at risk has not been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/7\">",
"     7",
"    </a>",
"    ]. This is due to wide biologic variation in normal fetal movement among healthy fetuses, as well as the wide variation in maternal perception of fetal activity.",
"   </p>",
"   <p>",
"    The minimal level of maternally perceived fetal movement consistent with fetal well-being has been termed the \"alarm limit.\" There is no evidence that any quantitative limit is more effective than qualitative maternal perception of DFM for identifying pregnancies at risk of adverse outcome.",
"   </p>",
"   <p>",
"    Objective limits are often defined by maternal counts of fetal kicks. Advantages of kick counts are that they are easy to perform, inexpensive, convenient, and keep the patient aware of her fetus' usual behavioral pattern.",
"   </p>",
"   <p>",
"    Various methods for counting fetal kicks have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/5,8-13\">",
"     5,8-13",
"    </a>",
"    ]. The following are four examples of criteria for reassurance of fetal well-being:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perception of at least 10 FMs during 12 hours of normal maternal activity",
"     </li>",
"     <li>",
"      Perception of least 10 FMs over two hours when the mother is at rest and focused on counting",
"     </li>",
"     <li>",
"      Perception of at least 4 FMs in one hour when the mother is at rest and focused on counting",
"     </li>",
"     <li>",
"      Perception of at least 10 FMs within 25 minutes in pregnancies 22 to 36 weeks and 35 minutes in pregnancies 37 or more weeks of gestation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only numerical limit that has been derived from a total population, and subsequently evaluated as a screening test in the same population, is the perception of 10 distinct movements during focused counting over a period of up to two hours, which is reassuring (\"count to 10\" method) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/8\">",
"     8",
"    </a>",
"    ]. In this study, the mean time interval to detect 10 movements was 20.9",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    18.1 minutes. Interventions for fetal compromise prompted by inadequate fetal activity tripled and were associated with a drop in fetal mortality among patients with DFM (from 44 per 1000 to 10 per 1000). The method has a high compliance and acceptance rate among women because it is convenient and doesn't take much time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/14\">",
"     14",
"    </a>",
"    ]; it is also clinically practical.",
"   </p>",
"   <p>",
"    While an active fetus is a reassuring sign that the baby is alive and in good condition, the use of fetal kick counting as a fetal surveillance tool has not achieved widespread acceptance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/15\">",
"     15",
"    </a>",
"    ]. This is in part because the optimal management of decreased fetal movement in the preterm and term baby has not been determined. Studies that have used maternal vigilance to fetal movement as a screening tool for fetal assessment may be using the wrong methods for subsequent fetal assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patient counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;We inform patients that their perception of fetal movement is a significant indicator of fetal well-being in the third trimester and they should pay attention to this activity daily to enable timely detection of DFM (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Prevalence and significance'",
"    </a>",
"    below). They are instructed to contact their health care provider for further evaluation if they perceive a significant and persistent reduction in fetal movement and never to wait longer than two hours if there is",
"    <strong>",
"     absent",
"    </strong>",
"    fetal movement. If the woman is in doubt about what constitutes DFM, we tell her that it is rare for a healthy baby in the third trimester to have fewer than 10 kicks over two consecutive hours at times when the fetus is usually active, and the mother is lying down and focused upon counting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/8,17\">",
"     8,17",
"    </a>",
"    ]. She is advised to call within 12 hours if she perceives decreased, but not absent, fetal movement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients and providers prefer use of a form for documenting daily movements. Forms provide an ongoing record of fetal movement for day-to-day and week-to-week comparisons [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence and significance of DFM in the second trimester are largely unknown (see below). We feel a prudent and pragmatic approach is for women over 24 weeks of gestation to contact their provider if they perceive a significant and persistent reduction in fetal movement from baseline, similar to the approach in the third trimester. If a woman presents with DFM before 24 weeks of gestation, she should undergo routine antenatal evaluation, including auscultation for the presence of a fetal heartbeat [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/20\">",
"     20",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVALENCE AND SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 40 percent of pregnant women become concerned about DFM one or more times during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/21\">",
"     21",
"    </a>",
"    ]. Most cases are transient. Four to 15 percent of pregnant women will contact their care provider because of DFM in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Third trimester DFM has been linked with adverse pregnancy outcomes related to fetal hypoxia and malnutrition. In some studies, women with third trimester DFM were more likely to have pregnancies complicated by impaired fetal growth, preterm birth, neonatal depression, emergency delivery, and fetal or neonatal death than women with normal fetal movement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/18\">",
"     18",
"    </a>",
"    ]. The increase in fetal mortality was illustrated in a prospective, population-based registry of 2313 women with third trimester singleton pregnancies with DFM who presented to health care facilities in Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/22\">",
"     22",
"    </a>",
"    ]. Many of these fetuses were already dead at presentation, but even among those who presented with a live fetus, mortality was higher than the mortality in the general obstetrical population:",
"    <span class=\"nowrap\">",
"     8.2/1000",
"    </span>",
"    births versus",
"    <span class=\"nowrap\">",
"     2.9/1000",
"    </span>",
"    births.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of normal fetal movement and other types of fetal biophysical activity (breathing movements, tone) virtually ensures functional integrity of fetal regulatory systems. When these regulatory systems are subjected to mild hypoxemia, DFM may represent a compensatory fetal behavioral response, analogous to the compensatory physiological response of redistribution of blood flow to essential organs. As hypoxemia becomes more severe and prolonged, DFM can be a manifestation of a decompensated state, indicative of imminent injury or death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Decreased maternal sensitivity to fetal movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequent fetal movement does not necessarily mean the fetus is compromised or even inactive. Poor perception of fetal activity may be due to early gestational age,",
"    <span class=\"nowrap\">",
"     decreased/increased",
"    </span>",
"    amniotic fluid volume, maternal position (sitting or standing versus lying), fetal position (anterior position of the fetal spine), anterior placenta, and maternal physical activity (or just being mentally distracted) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/1,4,17,22,26\">",
"     1,4,17,22,26",
"    </a>",
"    ]. The relationships between perception of fetal movement and parity and obesity are unclear. A sudden decrease in fetal movement, however, should not be attributed to ongoing pregnancy characteristics associated with decreased maternal sensitivity (eg,",
"    <span class=\"nowrap\">",
"     oligohydramnios/polyhydramnios,",
"    </span>",
"    anterior placenta), but evaluated as a potential marker of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Transient decreases in fetal movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient decreases in fetal activity can be due to fetal sleep states, maternal drug use (eg, sedatives), or maternal smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have evaluated any aspect of the management of DFM. Clinical approaches described in observational studies include: physical examination, nonstress or contraction stress tests, ultrasound examination (biophysical profile [BPP]), umbilical artery Doppler, testing for fetomaternal hemorrhage (eg, Kleihauer-Betke test), and amnioscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/24,28\">",
"     24,28",
"    </a>",
"    ]. The wide range of diagnostic approaches reflects efforts to detect acute fetal distress, subacute and chronic placental insufficiency, and other specific pathologies associated with DFM.",
"   </p>",
"   <p>",
"    The presentation of a woman with DFM should prompt a thorough evaluation of the current complaint and maternal, obstetric and fetal risk factors for adverse outcome. The goal of the evaluation is to rule out imminent fetal demise and to assess for common risk factors, such as fetal growth restriction and decreasing placental function. A plan of care is formulated based on the results of the evaluation.",
"   </p>",
"   <p>",
"    We suggest the following basic evaluation:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal viability should be documented by fetal heart rate assessment. Passive intrauterine motion or maternal intestinal activity may be perceived as DFM by the mother in the presence of a fetal demise.",
"   </p>",
"   <p>",
"    The woman's prenatal record should be reviewed for maternal medical or obstetrical conditions and characteristics that place the fetus at increased risk of adverse outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonstress test/cardiotocography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nonstress test (NST) provides immediate reassurance of fetal viability and well-being, but its value as the only screening tool for preventing perinatal morbidity or mortality in at-risk pregnancies has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/29\">",
"     29",
"    </a>",
"    ]. In the series of 2313 women with DFM in a Norwegian database, the NST was nonreactive or showed other nonreassuring patterns in 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link\">",
"     \"Antepartum fetal heart rate assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Additional testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ultrasound examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that ultrasound examination of pregnancies complicated by persistent DFM despite a reactive NST is a valuable assessment tool. This should include evaluation of fetal activity, fetal growth, amniotic fluid volume, and, in selected cases, fetal anatomic survey. Fetal anatomic survey and estimation of fetal weight are indicated if sonographic screening for congenital anomalies and growth restriction have not been performed previously or if there is a size-dates discrepancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/30\">",
"     30",
"    </a>",
"    ]. Growth restriction has been associated with a decrease in the number, quality, strength, and duration of fetal movements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/31\">",
"     31",
"    </a>",
"    ]. This is not surprising since the fetus depends on the placenta for both oxygen and nutrients, thus chronic placental insufficiency can affect both fetal oxygenation and fetal growth.",
"   </p>",
"   <p>",
"    In Norwegian series, women randomly assigned to perform fetal movement counting had slightly higher detection of fetal growth restriction than women who received usual care (20 of 23 fetuses [87.0 percent] versus 12 of 20 fetuses [60.0 percent], respectively; RR 1.5, 95% CI 1.0-2.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/32\">",
"     32",
"    </a>",
"    ]. Ultrasound examination detected an abnormality (eg, fetal growth restriction, oligohydramnios, polyhydramnios, congenital anomaly, low BPP score) in 12.6 percent of all consultations for DFM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/22,24\">",
"     22,24",
"    </a>",
"    ] and the population of pregnancies affected by DFM had birth weight centiles skewed downwards at all gestational ages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Doppler velocimetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler velocimetry is useful if fetal growth restriction has been identified on ultrasound examination. A study of 599 cases of DFM evaluated by nonstress testing found no additional benefit of Doppler assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/33\">",
"     33",
"    </a>",
"    ]. In the series from Norway, Doppler demonstrated a pathological pattern in 1 percent of the 1151 cases evaluated at hospitals that performed Doppler on most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/22\">",
"     22",
"    </a>",
"    ]. Most of these abnormalities were associated with growth restricted fetuses. When small for gestational age infants (birth weight less than the 10th percentile) and cases with nonreactive nonstress tests or abnormal ultrasound examination were excluded, Doppler velocimetry was abnormal in only 1 of 940 cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Testing for fetomaternal transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A maternal assay (Kleihauer-Betke stain or flow cytometry) to detect fetomaternal hemorrhage should be performed in the evaluation of the pregnant patient who presents with DFM and a sinusoidal fetal heart rate pattern, unexplained fetal tachycardia, or fetal hydrops on ultrasound associated with elevated middle cerebral artery Doppler velocity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3800?source=see_link\">",
"     \"Diagnosis and management of massive fetomaternal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large fetomaternal transfusion (FMT) is estimated to occur in 0.3 percent of pregnancies, and is a significant contributor to stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/34\">",
"     34",
"    </a>",
"    ]. Although testing for FMT in all cases of DFM has been suggested, DFM due to a large FMT is rare.",
"   </p>",
"   <p>",
"    One review described 134 cases of large FMT (&gt;50 mL) of which 78 were detected antepartum, and 21 survived [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/35\">",
"     35",
"    </a>",
"    ]. Thirty-three women had DFM as their only symptom. Fetal movement was absent in 17 cases for a period ranging from 24 hours to 7 days. In this group, six infants survived, five were stillborn, and five died in the neonatal period. The actual number of mothers who experienced DFM in this series was not well-documented. Subsequent case reports of severe and spontaneously occurring FMT detected antenatally included 13 cases which presented with DFM and one that did not [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/36-42\">",
"     36-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AND DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings at the initial consultation guide further management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Abnormal findings",
"      </strong>",
"      &mdash; Abnormal findings (eg, nonreactive nonstress test, low biophysical profile score, fetal growth restriction) are managed according to usual clinical standards. In our opinion, suspected fetal growth restriction with objective findings of low fetal activity is as worrisome.",
"     </li>",
"     <li>",
"      <strong>",
"       Persistent DFM and normal evaluation",
"      </strong>",
"      &mdash; There are no studies evaluating the optimal frequency and method of follow-up of pregnancies complicated by persistent DFM in which the antepartum evaluations discussed above are all normal. The strategy depends on whether the pregnancy has reached term and whether there are additional maternal or fetal risk factors for adverse outcome. In view of the high number of adverse outcomes despite normal findings that were observed in the Norwegian study of DFM, we feel vigilance is important in pregnancies with persistent DFM. As reassurance from antenatal testing is time limited, patients with persistent DFM, but a normal evaluation (including objective observation of fetal activity equivalent to a biophysical profile score &ge;8), should still be considered for repeated evaluation. The intervals at which such patients should be monitored depend on both subjective and objective measures of fetal activity, as well as the woman's risk profile. For patients with persistent concerns about perceived DFM, we recommend a follow-up appointment within 48 hours. This can be cancelled if normal fetal activity resumes. All patients are instructed to continue to monitor fetal movement and call their provider if they perceive a further decrease or absence of fetal movement.",
"      <br/>",
"      <br/>",
"      The rising risk of unexplained stillbirth after about 37 weeks of gestation, the diminishing hazard of induction at these gestations, and the possibility that delivery may be beneficial should all be considered in deciding how to manage women with persistent DFM and normal testing [",
"      <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/43-45\">",
"       43-45",
"      </a>",
"      ]. Counseling women about monitoring fetal activity is problematic if they never feel the baby move. We discuss the advantages and disadvantages of continued antepartum evaluation, but suggest induction after 37 weeks when the cervix is favorable, especially if there are additional risk factors for adverse outcome. There are no randomized trials demonstrating the efficacy and hazard of this approach. We believe no pregnancy with persistent DFM should continue postterm.",
"     </li>",
"     <li>",
"      <strong>",
"       Return of normal fetal activity and normal evaluation",
"      </strong>",
"      &mdash; Further follow-up is unwarranted in cases of DFM of short duration in which normal activity resumes during evaluation and the evaluation is normal. All patients are instructed to continue to monitor fetal movement and call their provider if they perceive recurrent persistent DFM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Cochrane systematic review of fetal movement counting for assessment of fetal well-being concluded there was insufficient evidence of a benefit of this intervention to allow a practice recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/16\">",
"     16",
"    </a>",
"    ]. A subsequent Cochrane review concluded there were no data from randomized trials to guide practice recommendations for management of DFM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We have implemented the counseling and evaluation strategy described above as a quality improvement project in Eastern Norway. After this intervention, the stillbirth rate in women with DFM fell from 4.2 to 2.4 percent (OR 0.51, 95% CI 0.32-0.81), without a significant increase in the number of women presenting for evaluation due to concerns for DFM (6.3 versus 6.6 percent after the intervention) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/25\">",
"     25",
"    </a>",
"    ]. The stillbirth rate in the overall study population fell from",
"    <span class=\"nowrap\">",
"     3.0/1000",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     2.0/1000",
"    </span>",
"    (OR 0.67, 95% CI 0.48-0.93). However, a prospective cohort study of time to count 10 fetal movements in a Norwegian population did not demonstrate significant differences between pregnancies with suboptimal versus normal outcomes, suggesting more research is needed on the optimum method for assessing DFM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RESEARCH GAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;More research in the area of fetal movement monitoring is needed, including assessing the sensitivity and specificity of fetal movement counting in detecting fetal compromise, the effectiveness of fetal movement counting for decreasing perinatal mortality in high-risk and low-risk pregnancies, and its acceptability and ease of use. The encouraging findings of the quality improvement project in Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15959/abstract/3\">",
"     3",
"    </a>",
"    ], implementing clinical practice guidelines and information for women across maternity hospitals, require confirmation in further studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women should be given information prenatally about normal and decreased fetal activity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal fetal movement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Decreased fetal movement (DFM)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rationale for maternal monitoring of fetal movement is based on the assumption that early recognition of decreased fetal movement makes it possible for the clinician to intervene at a stage when the fetus is still compensated, and thus prevent progression to fetal or neonatal death. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of pregnancies with decreased fetal movement should be performed in a timely fashion. We suggest that pregnant women contact their health care provider if they feel a major and persistent decrease in usual activity, or if there are fewer than 10 kicks over two hours at times when the fetus is usually active and the mother is focusing upon counting. Women should never wait overnight if there is perceived absence of fetal movement. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient counseling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the basic evaluation of pregnancies complicated by decreased fetal movement include review of the prenatal record and a nonstress test. Even in the setting of a reactive nonstress test, we suggest obtaining an ultrasound examination within 24 to 48 hours if not recently performed because these pregnancies are at two-fold increased risk of growth restriction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of patients with persistently decreased fetal movement depends on the gestational age and the presence of other identifiable risk factors for stillbirth. If no cause for decreased fetal movement is determined, we suggest pregnancies under 37 weeks of gestation be monitored with nonstress testing and ultrasound examination twice weekly. Given the diminishing hazard of induction after 37 weeks of gestation and the possibility that delivery may be beneficial, we suggest labor induction of these pregnancies when the cervix is favorable (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Follow-up and delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/1\">",
"      Gillieson M, Dunlap H, Nair R, Pilon M. Placental site, parity, and date of quickening. Obstet Gynecol 1984; 64:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/2\">",
"      Raynes-Greenow CH, Gordon A, Li Q, Hyett JA. A cross-sectional study of maternal perception of fetal movements and antenatal advice in a general pregnant population, using a qualitative framework. BMC Pregnancy Childbirth 2013; 13:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/3\">",
"      de Vries JI, Fong BF. Normal fetal motility: an overview. Ultrasound Obstet Gynecol 2006; 27:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/4\">",
"      Hijazi ZR, East CE. Factors affecting maternal perception of fetal movement. Obstet Gynecol Surv 2009; 64:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/5\">",
"      Valentin L, L&ouml;fgren O, Mars&aacute;l K, Gullberg B. Subjective recording of fetal movements. I. Limits and acceptability in normal pregnancies. Acta Obstet Gynecol Scand 1984; 63:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/6\">",
"      Patrick J, Campbell K, Carmichael L, et al. Patterns of gross fetal body movements over 24-hour observation intervals during the last 10 weeks of pregnancy. Am J Obstet Gynecol 1982; 142:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/7\">",
"      Flenady V, MacPhail J, Gardener G, et al. Detection and management of decreased fetal movements in Australia and New Zealand: a survey of obstetric practice. Aust N Z J Obstet Gynaecol 2009; 49:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/8\">",
"      Moore TR, Piacquadio K. A prospective evaluation of fetal movement screening to reduce the incidence of antepartum fetal death. Am J Obstet Gynecol 1989; 160:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/9\">",
"      Neldam S. Fetal movements as an indicator of fetal wellbeing. Lancet 1980; 1:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/10\">",
"      Grant A, Elbourne D, Valentin L, Alexander S. Routine formal fetal movement counting and risk of antepartum late death in normally formed singletons. Lancet 1989; 2:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/11\">",
"      Sadovsky E, Ohel G, Havazeleth H, et al. The definition and the significance of decreased fetal movements. Acta Obstet Gynecol Scand 1983; 62:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/12\">",
"      Pearson JF, Weaver JB. Fetal activity and fetal wellbeing: an evaluation. Br Med J 1976; 1:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/13\">",
"      Kuwata T, Matsubara S, Ohkusa T, et al. Establishing a reference value for the frequency of fetal movements using modified 'count to 10' method. J Obstet Gynaecol Res 2008; 34:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/14\">",
"      Smith CV, Davis SA, Rayburn WF. Patients' acceptance of monitoring fetal movement. A randomized comparison of charting techniques. J Reprod Med 1992; 37:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/15\">",
"      Heazell AE, Fr&oslash;en JF. Methods of fetal movement counting and the detection of fetal compromise. J Obstet Gynaecol 2008; 28:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/16\">",
"      Mangesi L, Hofmeyr GJ. Fetal movement counting for assessment of fetal wellbeing. Cochrane Database Syst Rev 2007; :CD004909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/17\">",
"      Minors DS, Waterhouse JM. The effect of maternal posture, meals and time of day on fetal movements. Br J Obstet Gynaecol 1979; 86:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/18\">",
"      Fr&oslash;en JF, Tveit JV, Saastad E, et al. Management of decreased fetal movements. Semin Perinatol 2008; 32:307.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.firstcandle.org/cms/wp-content/uploads/2010/09/Kicks-Count-ABC-Brochure-English1.pdf (Accessed on August 06, 2012).",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists. Green-top Guideline 57. Reduced Fetal Movements. file://www.rcog.org.uk/guidelines (Accessed on April 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/21\">",
"      Saastad E, Winje BA, Israel P, Fr&oslash;en JF. Fetal movement counting--maternal concern and experiences: a multicenter, randomized, controlled trial. Birth 2012; 39:10.",
"     </a>",
"    </li>",
"    <li>",
"     Tveit, JV, Saastad, E, Bordahl, PE, Stray-Pedersen, B, Froen, JF. The epidemiology of decreased fetal movements. Proceedings of the Norwegian Perinatal Society Conference, November 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/23\">",
"      Fr&oslash;en JF. A kick from within--fetal movement counting and the cancelled progress in antenatal care. J Perinat Med 2004; 32:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/24\">",
"      Fr&oslash;en JF, Saastad E, Tveit JV, et al. [Clinical practice variation in reduced fetal movements]. Tidsskr Nor Laegeforen 2005; 125:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/25\">",
"      Tveit JV, Saastad E, Stray-Pedersen B, et al. Reduction of late stillbirth with the introduction of fetal movement information and guidelines - a clinical quality improvement. BMC Pregnancy Childbirth 2009; 9:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/26\">",
"      Tuffnell DJ, Cartmill RS, Lilford RJ. Fetal movements; factors affecting their perception. Eur J Obstet Gynecol Reprod Biol 1991; 39:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/27\">",
"      Winje BA, R&oslash;islien J, Fr&oslash;en JF. Temporal patterns in count-to-ten fetal movement charts and their associations with pregnancy characteristics: a prospective cohort study. BMC Pregnancy Childbirth 2012; 12:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/28\">",
"      Sergent F, Lef&egrave;vre A, Verspyck E, Marpeau L. [Decreased fetal movements in the third trimester: what to do?]. Gynecol Obstet Fertil 2005; 33:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/29\">",
"      Pattison N, McCowan L. Cardiotocography for antepartum fetal assessment. Cochrane Database Syst Rev 2000; :CD001068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/30\">",
"      Heazell AE, Sumathi GM, Bhatti NR. What investigation is appropriate following maternal perception of reduced fetal movements? J Obstet Gynaecol 2005; 25:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/31\">",
"      Bekedam DJ, Visser GH, de Vries JJ, Prechtl HF. Motor behaviour in the growth retarded fetus. Early Hum Dev 1985; 12:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/32\">",
"      Saastad E, Winje BA, Stray Pedersen B, Fr&oslash;en JF. Fetal movement counting improved identification of fetal growth restriction and perinatal outcomes--a multi-centre, randomized, controlled trial. PLoS One 2011; 6:e28482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/33\">",
"      Dubiel M, Gudmundsson S, Thuring-J&ouml;nsson A, et al. Doppler velocimetry and nonstress test for predicting outcome of pregnancies with decreased fetal movements. Am J Perinatol 1997; 14:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/34\">",
"      Sebring ES, Polesky HF. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion 1990; 30:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/35\">",
"      Giacoia GP. Severe fetomaternal hemorrhage: a review. Obstet Gynecol Surv 1997; 52:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/36\">",
"      Bakas P, Liapis A, Giner M, et al. Massive fetomaternal hemorrhage and oxytocin contraction test: case report and review. Arch Gynecol Obstet 2004; 269:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/37\">",
"      Lau MS, Tan JV, Tan TY, et al. Idiopathic chronic fetomaternal haemorrhage resulting in hydrops--a case report. Ann Acad Med Singapore 2003; 32:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/38\">",
"      Malcus P, Bjorklund LJ, Lilja M, et al. Massive feto-maternal hemorrhage: diagnosis by cardiotocography, Doppler ultrasonography and ST waveform analysis of fetal electrocardiography. Fetal Diagn Ther 2006; 21:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/39\">",
"      Sueters M, Arabin B, Oepkes D. Doppler sonography for predicting fetal anemia caused by massive fetomaternal hemorrhage. Ultrasound Obstet Gynecol 2003; 22:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/40\">",
"      Thomas A, Mathew M, Unciano Moral E, Vaclavinkova V. Acute massive fetomaternal hemorrhage: case reports and review of the literature. Acta Obstet Gynecol Scand 2003; 82:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/41\">",
"      Weisberg L, Kingdom J, Keating S, et al. Treatment options in fetomaternal hemorrhage: four case studies. J Obstet Gynaecol Can 2004; 26:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/42\">",
"      Zizka Z, Calda P, Zlatohlavkova B, et al. Massive fetomaternal transplacental hemorrhage as a perinatology problem, role of ABO fetomaternal compatibility--case studies. Med Sci Monit 2001; 7:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/43\">",
"      Fr&oslash;en JF, Arnestad M, Frey K, et al. Risk factors for sudden intrauterine unexplained death: epidemiologic characteristics of singleton cases in Oslo, Norway, 1986-1995. Am J Obstet Gynecol 2001; 184:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/44\">",
"      Fretts RC, Elkin EB, Myers ER, Heffner LJ. Should older women have antepartum testing to prevent unexplained stillbirth? Obstet Gynecol 2004; 104:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/45\">",
"      Nicholson JM, Kellar LC, Cronholm PF, Macones GA. Active management of risk in pregnancy at term in an urban population: an association between a higher induction of labor rate and a lower cesarean delivery rate. Am J Obstet Gynecol 2004; 191:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/46\">",
"      Hofmeyr GJ, Novikova N. Management of reported decreased fetal movements for improving pregnancy outcomes. Cochrane Database Syst Rev 2012; 4:CD009148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15959/abstract/47\">",
"      Winje BA, Saastad E, Gunnes N, et al. Analysis of 'count-to-ten' fetal movement charts: a prospective cohort study. BJOG 2011; 118:1229.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 444 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15959=[""].join("\n");
var outline_f15_37_15959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL FETAL MOVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DECREASED FETAL MOVEMENT (DFM)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patient counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVALENCE AND SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Decreased maternal sensitivity to fetal movement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Transient decreases in fetal movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonstress test/cardiotocography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Additional testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ultrasound examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Doppler velocimetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Testing for fetomaternal transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FOLLOW-UP AND DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RESEARCH GAPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3800?source=related_link\">",
"      Diagnosis and management of massive fetomaternal hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_37_15960="Overview of vitamin K";
var content_f15_37_15960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of vitamin K",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15960/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15960/contributors\">",
"     Sassan Pazirandeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15960/contributors\">",
"     David L Burns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15960/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15960/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15960/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15960/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/37/15960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamins are a number of chemically unrelated families of organic substances that cannot be synthesized by humans but need to be ingested in the diet in small quantities to prevent disorders of metabolism. They are divided into water-soluble and fat-soluble vitamins (",
"    <a class=\"graphic graphic_table graphicRef63827 \" href=\"UTD.htm?12/15/12541\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    More than 50 years ago, Henrik Dam of Denmark discovered an \"antihemorrhagic factor\" that was capable of reversing dietary-induced bleeding disorders in chicks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/1\">",
"     1",
"    </a>",
"    ]. The name \"K\" comes from the",
"    <span class=\"nowrap\">",
"     German/Danish",
"    </span>",
"    word koagulationsvitamin (clotting vitamin) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1930,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    was first isolated by Doisy and his colleagues, as well as by Dam, from alfalfa sprouts [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/3\">",
"     3",
"    </a>",
"    ]. Until the 1980s, when chromatographic techniques were used, the mainstay of vitamin K isolation was through using chick bioassay [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will focus on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    . Overviews of the other fat-soluble vitamins, minerals and water-soluble vitamins are available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link\">",
"     \"Overview of vitamin A\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=see_link\">",
"     \"Overview of vitamin E\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=see_link\">",
"     \"Overview of dietary trace minerals\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link\">",
"     \"Overview of water-soluble vitamins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary vitamin K1 (phylloquinone or phytonadione) is found in green vegetables like spinach and broccoli (",
"    <a class=\"graphic graphic_table graphicRef78708 \" href=\"UTD.htm?37/43/38589\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/4\">",
"     4",
"    </a>",
"    ]. Gut micro-flora synthesizes vitamin K2 (menaquinones, including menatetrenone), which provides a portion of the dietary requirement of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/4\">",
"     4",
"    </a>",
"    ]. Vitamin K2 has approximately 60 percent of the activity of vitamin K1, by weight, but bioavailability of both forms varies substantially depending on other intraluminal nutrients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHEMISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    and its derivatives contain a 2-methyl-1, 4, naphthoquinone nucleus with a lipophilic side chain (",
"    <a class=\"graphic graphic_figure graphicRef66755 \" href=\"UTD.htm?39/17/40220\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    absorption requires intact pancreatic and biliary function and fat absorptive mechanisms. Dietary vitamin K is protein-bound and is liberated by the proteolytic action of pancreatic enzymes in the small intestine. Bile salts then solubilize vitamin K into micelles for absorption into enterocytes, where it is incorporated into chylomicrons, thereby facilitating absorption into the intestinal lymphatics and portal circulation for transport to the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    has a major role in coagulation pathways because it is a cofactor required for the activity of several key proteins containing carboxyglutamic acid residues. Several other proteins within the body (eg, osteocalcin) also contain carboxyglutamate residues and depend upon vitamin K for their activity (",
"    <a class=\"graphic graphic_table graphicRef60052 \" href=\"UTD.htm?35/48/36619\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=see_link\">",
"     \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Coagulation pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    is essential for activity of several carboxylase enzymes within the hepatic cells, and therefore is necessary for the activation of coagulation factors VII, IX, X, and prothrombin. These factors contain carboxyglutamic acid, which is carboxylated by gamma-glutamyl carboxylase, an endoplasmic enzyme found in mammalian cells (",
"    <a class=\"graphic graphic_figure graphicRef61632 \" href=\"UTD.htm?39/9/40094\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/2\">",
"     2",
"    </a>",
"    ]. Vitamin K is the active coenzyme in this process, providing energy for the reaction through oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/7\">",
"     7",
"    </a>",
"    ]. After carboxylation, these proteins gain affinity for the negatively charged phospholipids on the surface of platelets and promote coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antithrombotic effects of proteins C and S",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural anticoagulants, proteins S and C also require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    for their activity. Protein C, following its activation by thrombin, inactivates factors Va and VIIIa, thus inhibiting excess generation of thrombin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H2#H2\">",
"     \"Protein C deficiency\", section on 'Physiology of protein C'",
"    </a>",
"    .) Protein S also helps prevent excessive coagulation through its action as a cofactor for activated protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"     \"Protein S deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mechanism of action of the coumarin-like family",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coumarin-like anticoagulants, which are similar in structure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef66755 \" href=\"UTD.htm?39/17/40220\">",
"     figure 1",
"    </a>",
"    ), interrupt the vitamin K dependent carboxylation cycle by blocking reduction of the inactive vitamin K 2,3 epoxide to the active form of the vitamin (",
"    <a class=\"graphic graphic_figure graphicRef61632 \" href=\"UTD.htm?39/9/40094\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/4\">",
"     4",
"    </a>",
"    ]. Vitamin K administration is one of the methods used to reverse the effects of coumarin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H18#H18\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Surgery/invasive procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, since carboxylation of the coagulation factors occurs in the liver, patients with severely impaired liver function do not respond well to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    supplementation, and the coagulopathy is not as easily reversed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/10\">",
"     10",
"    </a>",
"    ]. In such cases, fresh frozen plasma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coagulant protein concentrates can be used to restore coagulant activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H20#H20\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Liver failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bone formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    is a cofactor for some proteins involved in bone mineralization, including osteocalcin (bone Gla protein) and matrix Gla protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link&amp;anchor=H1206099#H1206099\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Biochemistry of bone mineral matrix'",
"    </a>",
"    .) Clinical trials have examined the use of vitamin K1 (phylloquinone) or vitamin K2 for the treatment of osteoporosis, with conflicting results which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Vitamin K'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DEFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical signs and symptoms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    deficiency include easy bruisability, mucosal bleeding, splinter hemorrhages, melena, hematuria, or any other manifestations of impaired coagulation. Vitamin K deficiency in an otherwise healthy adult is rare. This is largely due to the wide distribution of phylloquinone in plants, menaquinone production by gut micro-flora, and because vitamin K is easily recycled within cells (",
"    <a class=\"graphic graphic_figure graphicRef61632 \" href=\"UTD.htm?39/9/40094\">",
"     figure 2",
"    </a>",
"    ). However, an acquired deficiency can occur secondary to drugs such as antibiotics. Patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    or those on long-term antibiotics are prone to develop vitamin K deficiency and require supplementation. Prolonged fasting or starvation also decreases vitamin K levels. Such patients are more sensitive to treatment with coumarin-based anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Daily value'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=see_link&amp;anchor=H18#H18\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Hematologic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22930453\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coagulation abnormalities caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    deficiency are manifested as prolonged prothrombin time (PT) and International Normalized Ratio (INR). When the deficiency is mild, only the PT may be prolonged, due to a predominant effect on factor VII. In severe vitamin K deficiency, both the PT and partial thromboplastin time (PTT) may be affected. Levels of PIVKA-II (Proteins induced in vitamin K absence) are more sensitive than PT in detecting vitamin K deficiency and may be helpful in monitoring patients with diseases predisposing to vitamin K deficiency. Vitamin K levels also can be measured directly but are impractical for clinical use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical use of coagulation tests\", section on 'Causes of prolonged PT'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    is a fat-soluble vitamin, thus any cause of fat malabsorption may result in vitamin K deficiency. Fat malabsorption may be caused by disorders of bile or pancreatic secretion, or by extensive disease or resection of the intestinal mucosa. As examples, patients with the following disorders are at risk for fat-soluble vitamin deficiencies and usually require supplementation and monitoring, as discussed in the corresponding topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystic fibrosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=see_link&amp;anchor=H18#H18\">",
"       \"Cystic fibrosis: Nutritional issues\", section on 'Vitamin K'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the treatment of primary biliary cirrhosis\", section on 'Deficiencies of fat soluble vitamins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary sclerosing cholangitis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Biliary atresia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=see_link&amp;anchor=H19844897#H19844897\">",
"       \"Biliary atresia\", section on 'Fat-soluble vitamin supplements'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Familial intrahepatic cholestasis and other inherited disorders associated with cholestasis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link\">",
"       \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intestinal diseases associated with malabsorption, such as active celiac disease, inflammatory bowel disease, or short bowel syndrome, may be associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      deficiency. This is particularly true if the terminal ileum is involved because this can cause maldigestion of the fat-soluble vitamins by reducing the bile salt pool. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=see_link\">",
"       \"Nutrient deficiencies in inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because the vitamin-K dependent coagulation factors are synthesized in the liver, severe parenchymal liver disease also may lead to deficiencies of these factors. In patients with severe liver disease and coagulation abnormalities, measurement of factors V and VII can help to distinguish between liver parenchymal dysfunction and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    malabsorption. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"     \"Coagulation abnormalities in patients with liver disease\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Antibiotics can contribute to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    deficiency by affecting intestinal bacteria, and also through direct effects on vitamin K activation in the liver. Most of the ingested vitamin K is absorbed in the distal small intestine. A number of microorganisms, which colonize the colon and distal ileum, synthesize absorbable vitamin K (vitamin K2, menaquinone). Many broad-spectrum antibiotics diminish this population of bacteria, limiting menaquinone production [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/12\">",
"     12",
"    </a>",
"    ]. Second and third generation antibiotics are associated with hypoprothrombinemia and have a weak coumarin-like effect in patients with low vitamin K stores [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/13\">",
"     13",
"    </a>",
"    ]. They cause vitamin K deficiency by inhibiting the function of vitamin K epoxide reductase enzyme in the liver, therefore impairing the recycling of vitamin K (",
"    <a class=\"graphic graphic_figure graphicRef61632 \" href=\"UTD.htm?39/9/40094\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extremely high doses of vitamin E and A antagonize",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/14\">",
"     14",
"    </a>",
"    ]. Hypervitaminosis A appears to reduce absorption of vitamin K, as suggested by the observation that the parenteral infusion of vitamin A (retinoic acid) does not increase the vitamin K requirement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/15\">",
"     15",
"    </a>",
"    ]. Very high doses of vitamin E also cause vitamin K deficiency, but do not appear to affect absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vitamin K deficient bleeding in the newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    deficiency is common in the newborn, and if vitamin K is not replaced, the infant is at risk for vitamin K deficient bleeding (VKDB), previously known as hemorrhagic disease of the newborn. This disorder is associated with cutaneous, gastrointestinal, and intracranial bleeding in neonates, typically developing within the first week of life.",
"   </p>",
"   <p>",
"    Newborn infants are at risk for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    deficiency because their immature liver does not efficiently utilize vitamin K. In addition, they tend to have low vitamin K stores because of the low vitamin K content of breast milk, a sterile gut, and poor placental transfer of vitamin K [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/17\">",
"     17",
"    </a>",
"    ]. In infants, the plasma concentrations of all vitamin K dependent factors are about 20 percent of the adult values. Within a month after birth, the levels rise to within normal limits [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/18\">",
"     18",
"    </a>",
"    ]. The risk of developing VKDB is further increased by maternal ingestion during pregnancy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or other coumarin-like anticoagulants, certain antibiotics (ie, cephalosporins), and some anticonvulsants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To prevent VKDB, the American Academy of Pediatrics recommends administration of parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    at birth, and supplementation of infant formulas with vitamin K [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link\">",
"     \"Overview of the routine management of the healthy newborn infant\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H19\">",
"     'Prevention of vitamin K deficient bleeding in newborns'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EXCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    toxicity is very rare, and a tolerable upper limit for consumption has not been defined (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"UTD.htm?19/31/19967\">",
"     table 4",
"    </a>",
"    ). Menadione, a synthetic water-soluble form of vitamin K, can cause hemolytic anemia, hyperbilirubinemia, jaundice, and kernicterus in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/20\">",
"     20",
"    </a>",
"    ]. Menadione has been used in premature or low-birth-weight newborns and it may precipitate kernicterus only in high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/21\">",
"     21",
"    </a>",
"    ]. However, this form of vitamin K supplementation is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     REQUIREMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Daily value",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary source of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    in the diet is from leafy green vegetables (",
"    <a class=\"graphic graphic_table graphicRef78708 \" href=\"UTD.htm?37/43/38589\">",
"     table 2",
"    </a>",
"    ). The dietary requirement, expressed as adequate intake (AI) is 90 micrograms daily in women and 120 micrograms daily in men (",
"    <a class=\"graphic graphic_table graphicRef81151 \" href=\"UTD.htm?19/31/19967\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25044870\">",
"    <span class=\"h3\">",
"     Parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    supplementation. Vitamin K is included in most brands of standard multivitamin mix added to the parenteral nutrition solution. A typical daily dose of adult injectable multivitamins for parenteral nutrition includes 150 mcg of vitamin K1 (phytonadione).&nbsp;For patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , daily intake of 150 mcg of vitamin K1 has not been associated with a requirement for excessive doses of warfarin, or sub-therapeutic anticoagulation, as long as the anticoagulation regimen is appropriately monitored and doses are adjusted as needed. Nonetheless, for patients on warfarin, some providers select a brand of multivitamin mix that does not contain vitamin K (eg, MVI-12&reg;). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Interference with oral anticoagulant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study of healthy subjects stably anticoagulated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11256?source=see_link\">",
"     acenocoumarol",
"    </a>",
"    , use of food supplements providing up to 100",
"    <span class=\"nowrap\">",
"     micrograms/day",
"    </span>",
"    of vitamin K1 did not significantly interfere with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/23\">",
"     23",
"    </a>",
"    ]. The threshold dose of vitamin K1 causing a statistically significant lowering of the INR in these subjects was 150",
"    <span class=\"nowrap\">",
"     micrograms/day,",
"    </span>",
"    an amount easily exceeded following the ingestion of one-half cup of kale (",
"    <a class=\"graphic graphic_table graphicRef78708 \" href=\"UTD.htm?37/43/38589\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the cause of deficiency,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    can be administered in doses of one to 25 mg via oral, intramuscular, subcutaneous, or intravenous routes. When vitamin K deficiency occurs in patients who are also receiving coumarin-like anticoagulants, doses of vitamin K should be minimized in order to prevent refractoriness to further anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H35#H35\">",
"     \"Therapeutic use of warfarin\", section on 'Excessive anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     Vitamin K",
"    </a>",
"    status can be determined indirectly by measuring vitamin K-dependent factors (ie, prothrombin, factors VII, IX, X, or protein C). In patients who are vitamin K deficient, levels of these factors often are less than 50 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/17\">",
"     17",
"    </a>",
"    ]. Measurement of des-gamma-carboxyprothrombin (DCP) in plasma is another more sensitive way of determining vitamin K deficiency. In normal subjects, DCP is zero; it is elevated in vitamin K deficiency from whatever cause",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention of vitamin K deficient bleeding in newborns",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is general consensus that all babies should receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    . Standard treatment is with vitamin K1 (0.5 to 1 mg IM) administered at birth. For healthy, exclusively breastfed, term infants, an alternative strategy may be oral vitamin K1 (2 mg orally with the first feed and at one, four, and eight weeks of age). However, oral supplements may be less effective in preventing late-onset vitamin K deficient bleeding in infants, and no approved oral preparation is available in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link\">",
"     \"Overview of the routine management of the healthy newborn infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Adequate Intake for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"     vitamin K",
"    </a>",
"    , as defined by the Food and Nutrition Board is not increased for lactating mothers. However, one study suggests that exclusively breast-fed infants often have low plasma vitamin K concentrations, and that this can be prevented by supplementation of the mothers' diet with 5 mg of vitamin K1 (phylloquinone) throughout the first 12 weeks of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15960/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. No studies have evaluated whether maternal supplementation with vitamin K has any clinically important benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H915632\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary vitamin K1 (phylloquinone or phytonadione) is found in green vegetables like spinach and broccoli (",
"      <a class=\"graphic graphic_table graphicRef78708 \" href=\"UTD.htm?37/43/38589\">",
"       table 2",
"      </a>",
"      ). The dietary requirement, expressed as adequate intake (AI) is 90 micrograms daily in women and 120 micrograms daily in men (",
"      <a class=\"graphic graphic_table graphicRef81151 \" href=\"UTD.htm?19/31/19967\">",
"       table 4",
"      </a>",
"      ). Gut micro-flora synthesizes vitamin K2 (menaquinones, including menatetrenone), which provides a portion of the dietary requirement of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      . Vitamin K absorption requires intact pancreatic and biliary function and fat absorptive mechanisms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sources'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"       Vitamin K",
"      </a>",
"      is essential for activity of several carboxylase enzymes within the hepatic cells and therefore is necessary for the activation of coagulation factors VII, IX, X, and prothrombin. The natural anticoagulants proteins S and C also require vitamin K for their activity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Actions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coumarin-like anticoagulants are similar in structure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef66755 \" href=\"UTD.htm?39/17/40220\">",
"       figure 1",
"      </a>",
"      ) and interrupt the vitamin K dependent carboxylation cycle. Vitamin K administration is one of the methods used to reverse the effects of coumarin. Patients with severely impaired liver function do not respond well to vitamin K supplementation, and coumarin-induced coagulopathy is not as easily reversed. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mechanism of action of the coumarin-like family'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"       Vitamin K",
"      </a>",
"      is a cofactor for some proteins involved in bone mineralization. Clinical trials have examined the use of vitamin K1 (phylloquinone) or vitamin K2 for the treatment of osteoporosis, with conflicting results. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bone formation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H22#H22\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Vitamin K'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Clinical signs and symptoms of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"       vitamin K",
"      </a>",
"      deficiency include easy bruisability, mucosal bleeding, splinter hemorrhages, melena, hematuria, or any other manifestations of impaired coagulation. Vitamin K deficiency in an otherwise healthy adult is rare. Patients at risk for vitamin K deficiency include those on long-term broad-spectrum antibiotics or those with fat malabsorption for a variety of reasons, including disorders of bile or pancreatic secretion, or extensive disease or resection of the intestinal mucosa. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Causes'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"       Vitamin K",
"      </a>",
"      deficiency is common in the newborn because of immature liver function and low transfer of vitamin K through the placenta or breast milk. If vitamin K is not replaced, the infant is at risk for vitamin K deficient bleeding (VKDB), previously known as hemorrhagic disease of the newborn. This disorder is associated with cutaneous, gastrointestinal, and intracranial bleeding in neonates, typically developing within the first week of life. To prevent VKDB, standard treatment is with vitamin K1 (0.5 to 1 mg IM) administered at birth. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vitamin K deficient bleeding in the newborn'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Prevention of vitamin K deficient bleeding in newborns'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3479?source=see_link\">",
"       Vitamin K",
"      </a>",
"      deficiency causes prolonged prothrombin time (PT) and International Normalized Ratio (INR). In more severe vitamin K deficiency, the partial thromboplastin time (PTT) also may be affected. Levels of PIVKA-II (proteins induced in vitamin K absence) are more sensitive than PT in detecting vitamin K deficiency and may be helpful in monitoring patients with diseases predisposing to vitamin K deficiency. (See",
"      <a class=\"local\" href=\"#H22930453\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/1\">",
"      Dam H. The antihemorrhagic vitamin of the chick: Occurrence and chemical nature. Nature 1935; 135:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/2\">",
"      Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am 2000; 14:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/3\">",
"      Dam H, Geiger A, Glavind J, et al. olierung des Vitamins K in hochgereinigter Form. Helv Chim Acta 1939; 22:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/4\">",
"      Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999; 93:1798.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition, American Academy of Pediatrics. Fat-soluble vitamins. In: Pediatric Nutrition Handbook, 6, Kleinman, RE (Eds), American Academy of Pediatrics, Elk Grove Village 2009. p.468.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/6\">",
"      Shearer MJ. Vitamin K. Lancet 1995; 345:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/7\">",
"      Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990; 75:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/8\">",
"      Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/9\">",
"      Fair DS, Marlar RA, Levin EG. Human endothelial cells synthesize protein S. Blood 1986; 67:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/10\">",
"      Larson AE, Friedman PA, Suttie JW. Vitamin K-dependent carboxylase. Stoichiometry of carboxylation and vitamin K 2,3-epoxide formation. J Biol Chem 1981; 256:11032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/11\">",
"      Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/12\">",
"      Hooper CA, Haney BB, Stone HH. Gastrointestinal bleeding due to vitamin K deficiency in patients on parenteral cefamandole. Lancet 1980; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/13\">",
"      Shearer MJ, Bechtold H, Andrassy K, et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1988; 28:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/14\">",
"      Light RF, Alscher RP, Frey CN. VITAMIN A TOXICITY AND HYPOPROTHROMBINEMIA. Science 1944; 100:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/15\">",
"      Smith FR, Goodman DS. Vitamin A transport in human vitamin A toxicity. N Engl J Med 1976; 294:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/16\">",
"      Bettger WJ, Jones JP, Olson RE. Effect of alpha-tocopherol and alpha-tocopherolquinone on vitamin K-dependent carboxylation in the rat. Fed Proc 1982; 41:344.",
"     </a>",
"    </li>",
"    <li>",
"     Olson R. Vitamin K. In: Modern Nutrition in Health and Disease, Shils M, Olson J, Shike M, et al (Eds), Lippincott, Philadelphia 2000. p.363.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/18\">",
"      Motohara K, Endo F, Matsuda I. Effect of vitamin K administration on acarboxy prothrombin (PIVKA-II) levels in newborns. Lancet 1985; 2:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/19\">",
"      American Academy of Pediatrics. Committee statement, Committee on Nutrition. Vitamin K supplementation for infants receiving milk substitute infant formulas and for those with fat malabsorption. Pediatrics 1971; 48:483.",
"     </a>",
"    </li>",
"    <li>",
"     McLaren  D. Clinical manifestations of human vitamin and mineral disorders. In: Modern Nutrition in Health and Disease, Shils M, Olson J, Shike M, et al (Eds), Lippincott, Philadelphia 2000. p.485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/21\">",
"      Chawla D, Deorari AK, Saxena R, et al. Vitamin K1 versus vitamin K3 for prevention of subclinical vitamin deficiency: a randomized controlled trial. Indian Pediatr 2007; 44:817.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Nutrition Board of the Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc (2000). National Academies Press, Washington DC, 2000. p. 162-196 file://books.nap.edu/openbook.php?isbn=0309072794 (Accessed on July 23, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/23\">",
"      Schurgers LJ, Shearer MJ, Hamuly&aacute;k K, et al. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004; 104:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/24\">",
"      Blanchard RA, Furie BC, Kruger SF, et al. Immunoassays of human prothrombin species which correlate with functional coagulant activities. J Lab Clin Med 1983; 101:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/25\">",
"      Greer FR. Are breast-fed infants vitamin K deficient? Adv Exp Med Biol 2001; 501:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15960/abstract/26\">",
"      Greer FR, Marshall SP, Foley AL, Suttie JW. Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements. Pediatrics 1997; 99:88.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2624 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15960=[""].join("\n");
var outline_f15_37_15960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H915632\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHEMISTRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Coagulation pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antithrombotic effects of proteins C and S",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mechanism of action of the coumarin-like family",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bone formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22930453\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vitamin K deficient bleeding in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EXCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Daily value",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25044870\">",
"      - Parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Interference with oral anticoagulant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention of vitamin K deficient bleeding in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H915632\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2624\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2624|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/17/40220\" title=\"figure 1\">",
"      Vitamin K and warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/9/40094\" title=\"figure 2\">",
"      Vitamin K pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2624|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/15/12541\" title=\"table 1\">",
"      Clinical symptoms of selected vitamin deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/43/38589\" title=\"table 2\">",
"      Vitamin K foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/48/36619\" title=\"table 3\">",
"      Known Gla-containing proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/31/19967\" title=\"table 4\">",
"      Fat sol vit DRI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39929?source=related_link\">",
"      Biliary atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15754?source=related_link\">",
"      Cystic fibrosis: Nutritional issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43113?source=related_link\">",
"      Nutrient deficiencies in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39226?source=related_link\">",
"      Overview of dietary trace minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_37_15961="Disseminated intravascular coagulation during pregnancy";
var content_f15_37_15961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disseminated intravascular coagulation during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15961/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15961/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15961/contributors\">",
"     Kirk D Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15961/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15961/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15961/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15961/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/37/15961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is a pathologic disruption of the finely-balanced process of hemostasis. Massive activation of the clotting cascade results in widespread thrombosis, which leads to depletion of platelets and coagulation factors and excessive thrombolysis. The end result is multiorgan failure and hemorrhage.",
"   </p>",
"   <p>",
"    DIC was first described in 1901 as a state of \"temporary hemophilia\" in two pregnant women; one had a retained fetal demise and the other had a placental abruption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/1\">",
"     1",
"    </a>",
"    ]. Peripartum hemorrhage is estimated to account for 1 to 5 percent of all cases of DIC in high-resource countries; the frequency is higher in low-resource countries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/2\">",
"     2",
"    </a>",
"    ]. In a study of discharge coding data from the United States Nationwide Inpatient Sample, the prevalence of DIC between 1998 and 2009 increased by 35.5 percent, from 9.2 to 12.5 per 10,000 delivery hospitalizations. DIC accounted for approximately one-quarter of maternal deaths during that period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any patient in DIC presents a major management challenge, and this challenge is further complicated when a viable fetus is also present. For example, delaying delivery to transfuse the mother in DIC may not be in the best interest of a fetus with a nonreassuring fetal heart rate tracing, whereas performing an emergency cesarean delivery on a mother in DIC may not be in her best interest. Even in the setting of fetal demise, labor and delivery of a woman in DIC carries the potential for catastrophic hemorrhage.",
"   </p>",
"   <p>",
"    This topic will focus upon DIC related to pregnancy. Broader discussions of the pathogenesis, clinical manifestations, diagnosis, and treatment of DIC can be found separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1949821\">",
"    <span class=\"h1\">",
"     PREGNANCY COMPLICATIONS THAT MAY LEAD TO DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common pregnancy complications that may lead to DIC are [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abruptio placentae",
"     </li>",
"     <li>",
"      Severe preeclampsia, eclampsia, or HELLP syndrome",
"     </li>",
"     <li>",
"      Amniotic fluid embolism",
"     </li>",
"     <li>",
"      Acute fatty liver of pregnancy",
"     </li>",
"     <li>",
"      Dead fetus syndrome",
"     </li>",
"     <li>",
"      Septic abortion",
"     </li>",
"     <li>",
"      Massive hemorrhage, which may be a consequence of disorders such as placenta previa, uterine rupture, placenta accreta, or postpartum uterine atony",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intrauterine fetal demise as an inciting event is much less common than in previous decades, given that fetal demise is readily diagnosed by ultrasound examination and most patients elect to terminate the pregnancy shortly thereafter. This avoids development of coagulopathy, which is most common when the demised fetus is retained in utero for at least four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/5\">",
"     5",
"    </a>",
"    ]. Septic abortion is a complication of unsafe abortion, which is most common in areas lacking providers with the necessary skills to perform abortion or in environments that do not conform to minimal medical standards, or both. &nbsp;",
"   </p>",
"   <p>",
"    In the general population, the most common events that may initiate DIC are sepsis, tissue",
"    <span class=\"nowrap\">",
"     trauma/destruction,",
"    </span>",
"    and cancer (",
"    <a class=\"graphic graphic_table graphicRef58104 \" href=\"UTD.htm?8/28/8652\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND PATHOGENESIS OF DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pregnancy, the coagulation system is in an activated state to prevent excessive bleeding peripartum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21703?source=see_link\">",
"     \"Hematologic changes in pregnancy\"",
"    </a>",
"    .) In addition to systemic changes in coagulation factors, trophoblast cells that line the vascular bed of the placenta strongly express tissue factor, similar to other vascular endothelial cells. In normal coagulation, tissue factor binds to factor VIIa. This complex generates factor Xa, which binds to its cofactor, Va, to convert prothrombin to thrombin. The latter cleaves fibrinogen to fibrin and simultaneously causes platelet aggregation. This sequence is normally tightly regulated by multiple hemostatic mechanisms, including tissue factor pathway inhibitor, antithrombin, and activated protein C.",
"   </p>",
"   <p>",
"    In DIC, however, these physiologic regulatory mechanisms are overwhelmed or incapacitated, so thrombin production is not contained. Ongoing, uncontrolled, excessive production of thrombin leads to widespread intravascular fibrin deposition, resulting in end organ",
"    <span class=\"nowrap\">",
"     damage/failure.",
"    </span>",
"    In addition, widespread fibrinolysis, generation of fibrin degradation products, and depletion of coagulation factors and platelets (consumptive coagulopathy) result in a profound bleeding diathesis (",
"    <a class=\"graphic graphic_algorithm graphicRef78959 \" href=\"UTD.htm?32/4/32846\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In pregnancy, this cascade may be initiated by significant damage to fetoplacental tissue, as in abruptio placentae or dead fetus syndrome. Excessive exposure to tissue factor can also result from widespread endothelial damage related to hemorrhagic shock or to endothelial dysfunction related to",
"    <span class=\"nowrap\">",
"     preeclampsia/HELLP,",
"    </span>",
"    which is characterized by platelet adhesion and activation and formation and deposition of fibrin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/2\">",
"     2",
"    </a>",
"    ]. Obstetric DIC may also be triggered by profound loss of clotting factors due to hemorrhage, and by failure to produce clotting factors due to acute fatty liver. An interaction between DIC and systemic inflammatory response syndrome has also been described, and plays a role in the pathogenesis of DIC in sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1950009\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIC should be suspected in pregnant women with pregnancy complications associated with DIC (abruptio placentae, severe",
"    <span class=\"nowrap\">",
"     preeclampsia/HELLP",
"    </span>",
"    syndrome, amniotic fluid embolism, acute fatty liver of pregnancy, dead fetus septic abortion, massive hemorrhage), and any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding: severe bleeding (eg, vaginal, intrauterine, intraabdominal)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diffuse oozing of blood from skin (at intravenous sites) or mucosa (from a bladder catheter)",
"     </li>",
"     <li>",
"      Shock (tachycardia, hypotension, weak peripheral pulses, altered mental status, cool extremities, narrow pulse pressure [&lt;25 mmHg])",
"     </li>",
"     <li>",
"      Dyspnea, hemoptysis",
"     </li>",
"     <li>",
"      Acute renal failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1960559\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of DIC is based on the presence of typical clinical features supported by laboratory findings of coagulopathy. Laboratory findings include prolongation of the prothrombin, activated partial thromboplastin, and thrombin times; thrombocytopenia; elevated fibrin-related degradation products; and low fibrinogen concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/7\">",
"     7",
"    </a>",
"    ]. Reduction in fibrinogen is the least sensitive test and a late finding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that the prothrombin time and activated partial thromboplastin time may be slightly shorter, the platelet count may be slightly lower, and the fibrinogen and D-dimer levels may be significantly higher in normal women in late pregnancy than in nonpregnant women (",
"    <a class=\"graphic graphic_table graphicRef81137 \" href=\"UTD.htm?37/33/38424\">",
"     table 2",
"    </a>",
"    ). This state of compensated, accelerated intravascular coagulation is thought to be important for maintenance of the uterine-placental interface and preparation for the hemostatic challenge of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21703?source=see_link\">",
"     \"Hematologic changes in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rarely necessary in the obstetrical setting where DIC is typically fulminant, serial laboratory assessment showing a progressively increasing time for coagulation tests, decreasing platelet counts, increasing values for D-dimer and fibrin-degradation products, and falling fibrinogen levels can help distinguish mild DIC from normal pregnancy-related changes in these laboratory values.",
"   </p>",
"   <p>",
"    Scoring systems are not necessary for diagnosis of DIC, but some clinicians find them helpful. The International Society of Thrombosis and Haemostasis (ISTH) diagnostic scoring system assigns points and considers a score &ge;5 consistent with overt DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1 point for platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL,",
"      </span>",
"      2 points for",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      2 points for moderate increase in fibrin-related degradation markers, 3 points for strong increase",
"     </li>",
"     <li>",
"      1 point for prothrombin time prolonged by &gt;3 and &lt;6 seconds, 2 points if prolonged &ge;6 seconds",
"     </li>",
"     <li>",
"      1 point for fibrinogen &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A score of &lt;5 may indicate nonovert DIC and does not exclude the possibility that overt DIC is in the process of developing. This system has sensitivity and specificity of 93 and 98 percent, respectively, for diagnosis of DIC in the general population and has been validated in a nonpregnant population in a prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Japanese Association for Acute Medicine also developed a scoring system; a score of &ge;4 is consistent with DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1 point for platelet count 80,000 to",
"      <span class=\"nowrap\">",
"       120,000/microL,",
"      </span>",
"      3 points for",
"      <span class=\"nowrap\">",
"       &lt;80,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      1 point for fibrin degradation products &ge;10 and &lt;25",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      3 points for &ge;25",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"     </li>",
"     <li>",
"      1 point for prothrombin ratio (patient",
"      <span class=\"nowrap\">",
"       value/normal",
"      </span>",
"      value) &ge;1.2",
"     </li>",
"     <li>",
"      1 point for &ge;3 systemic inflammatory response syndrome criteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with the ISTH system, this system has been validated, but not in pregnant women.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key elements in managing the pregnant woman with DIC are to identify and treat the underlying disorder and provide supportive care, particularly replacement of blood products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Initial steps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial considerations in evaluation and management of the undelivered gravida in DIC are listed below. Management of postpartum hemorrhage is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Notify the anesthesia service",
"      </strong>",
"      &mdash; Notify the anesthesia staff for assistance with patient management and to provide anesthetic support for delivery. Epidural and spinal anesthesia are generally contraindicated in patients with a severe bleeding diathesis because of risk of epidural hematoma.",
"     </li>",
"     <li>",
"      <strong>",
"       Establish intravenous access and begin fluid resuscitation",
"      </strong>",
"      &mdash; Establish intravenous access peripherally with at least two large bore (16 gauge or larger) catheters and infuse crystalloid to support blood pressure (systolic &ge;90 mmHg) and maintain urine output (at least 0.5",
"      <span class=\"nowrap\">",
"       mL/kg/hour).",
"      </span>",
"      The best approach to fluid resuscitation remains controversial. A common formula is 3 liters isotonic saline per 1 liter estimated blood loss (&ldquo;three to one rule&rdquo;).",
"     </li>",
"     <li>",
"      <strong>",
"       Notify the blood bank",
"      </strong>",
"      <strong>",
"       and initiate transfusion therapy",
"      </strong>",
"      &mdash; Transfusion for treatment of DIC is appropriate in obstetrical patients since they have or are at high risk for serious bleeding or are likely to require an invasive procedure. Notify the blood bank of the potential need for massive transfusion and initiate a massive transfusion protocol, if available (",
"      <a class=\"graphic graphic_table graphicRef53516 \" href=\"UTD.htm?33/5/33886\">",
"       table 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Type and cross match a minimum of 6 units packed red blood cells, 6 units fresh frozen plasma, 10 bags of cryoprecipitate, and 1 six-pack of platelets. In most instances, preparation of fully typed and cross-matched blood requires at least 20 minutes. Clinicians can begin transfusion immediately using type O Rh(D)-negative pRBCs, if necessary, and then switch to type-specific or typed and cross matched pRBCs when available. Uncross-matched fresh frozen plasma is type AB (either Rh positive or negative) and can be used when transfusion is necessary prior to obtaining crossed-matched fresh frozen plasma.",
"      <br/>",
"      <br/>",
"      If there is inadequate blood for transfusion, local hospitals should be contacted and local and state law enforcement officials notified to provide expedited transport of needed blood products. The American Red Cross is another resource for blood products (call",
"      <span class=\"nowrap\">",
"       1-800-RED-CROSS/",
"      </span>",
"      1-800-733-2767 or local chapter).",
"      <br/>",
"      <br/>",
"      Many massive transfusion protocols recommend transfusion of red blood cells, fresh frozen plasma, and platelets in a ratio of 1:1:1 (termed hemostatic resuscitation) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. Note that 1 unit of apheresis platelets is equivalent to 6 units of non-apheresis (ie, random donor or whole-blood derived) platelets. A one to one ratio of packed red blood cells to fresh frozen plasma has been associated with higher survival in trauma patients than higher ratios (ie, more packed red blood cells than fresh frozen plasma) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/16-24\">",
"       16-24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It is important to correct abnormally low fibrinogen levels, which commonly occur in obstetrical patients with massive bleeding. Cryoprecipitate, a source of concentrated fibrinogen, can take up to 45 minutes to thaw and become available for transfusion. Clinicians need to order cryoprecipitate with enough advance planning to allow for the thawing time. A fibrinogen concentration below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      is generally treated with 10 units of cryoprecipitate (each unit of cryoprecipitate comes from one unit of whole blood, and raises the fibrinogen level by about 5",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=see_link\">",
"       \"Clinical use of plasma components\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Lyophilized fibrinogen (RiaSTAP&trade;, a human",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/20/14659?source=see_link\">",
"       fibrinogen concentrate",
"      </a>",
"      ) can be immediately reconstituted for use in correcting low fibrinogen levels, but it is expensive [",
"      <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Massive blood transfusion is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"       \"Massive blood transfusion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H3250855#H3250855\">",
"       \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion of blood products'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Maintain oxygenation",
"      </strong>",
"      &mdash; Keep arterial oxygen saturation above 95 percent.",
"     </li>",
"     <li>",
"      <strong>",
"       Avoid hypothermia",
"      </strong>",
"      &mdash; The patient should be kept warm with warmed blankets and other interventions (eg, Bair Hugger forced-air warming system), as needed. If large volumes of fluid and blood products are given, the infused",
"      <span class=\"nowrap\">",
"       fluids/blood",
"      </span>",
"      products should be warmed so they are close to body temperature to prevent a significant drop in maternal core temperature.",
"     </li>",
"     <li>",
"      <strong>",
"       Identify and address the triggering event",
"      </strong>",
"      &mdash; The cornerstone of therapy is to identify the underlying disorder leading to DIC and initiate appropriate treatment for that disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Sepsis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Septic abortion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=see_link\">",
"       \"Spontaneous abortion: Management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fetal demise (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/35/1591?source=see_link\">",
"       \"Diagnosis and management of stillbirth\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Amniotic fluid embolism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=see_link\">",
"       \"Amniotic fluid embolism syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Abruptio placentae (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34663?source=see_link\">",
"       \"Placental abruption: Management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      HELLP syndrome, severe preeclampsia, eclampsia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"       \"Preeclampsia: Management and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link\">",
"       \"Eclampsia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute fatty liver (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"       \"Acute fatty liver of pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hemorrhage (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42952?source=see_link\">",
"       \"Management of placenta previa\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link&amp;anchor=H15065397#H15065397\">",
"       \"Choosing the route of delivery after cesarean birth\", section on 'Uterine rupture'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link\">",
"       \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"       \"Overview of postpartum hemorrhage\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Order laboratory tests",
"      </strong>",
"      &mdash; When DIC is suspected clinically, an appropriate baseline panel consisting of a complete blood count, prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count, fibrinogen level, and a fibrin-related degradation marker (eg, D-dimer) should be obtained promptly for confirmation of the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Appropriate cultures (eg, blood, urine, amniotic fluid) should be obtained in septic patients.",
"      <br/>",
"      <br/>",
"      Prior to the return of the first set of laboratory studies, a red top tube (ie, no additives) containing 5 mL blood can be observed for clotting (Lee and White test). At room temperature, if the blood in the tube clots within 8 to 10 minutes and the clot remains intact, the patient likely has adequate fibrinogen stores. If the blood in the tube does not clot or an initial clot dissolves, it is likely that the patient is markedly deficient in key clotting factors [",
"      <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Assess blood loss",
"      </strong>",
"      &mdash; Although not very accurate, antepartum blood loss can be estimated by collection in a volumetric flask, or by weighing",
"      <span class=\"nowrap\">",
"       pads/towels",
"      </span>",
"      used to soak up the blood. In cases of severe abruption with concealed hemorrhage, the magnitude of blood loss can be estimated and monitored using a combination of parameters, including hourly assessment of changes in fundal height, clot volume on ultrasound examination, urine output, and serial",
"      <span class=\"nowrap\">",
"       hemoglobin/hematocrit",
"      </span>",
"      assessment.",
"      <br/>",
"      <br/>",
"      Blood loss is evaluated indirectly by assessment of vital signs; however, pregnant women display changes in vital signs later than nonpregnant women with similar blood loss. We utilize a protocol developed for the management of obstetrical hemorrhage. Hemodynamic instability is diagnosed when systolic BP is &lt;100 mmHg, pulse is &gt;100 bpm, tilt test is positive (20 bpm increase or decrease in systolic pressure), and urine output is &lt;30 mL per hour. Other signs and symptoms of hemodynamic instability include altered level of consciousness, shortness of breath, cold clammy skin, and pallor.",
"     </li>",
"     <li>",
"      <strong>",
"       Notify the pediatric service",
"      </strong>",
"      &mdash; The pediatric service should be notified so they can prepare for the birth of a possibly premature",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      compromised infant. If time permits, they may counsel the parents about newborn issues, as needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Follow-up laboratory tests and transfusion targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;We draw laboratory studies initially every 30 minutes to guide blood product replacement, and we transfuse blood products to achieve the following minimum levels for delivery (",
"    <a class=\"graphic graphic_table graphicRef53854 \" href=\"UTD.htm?41/3/42043\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &ge;50,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Fibrinogen &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Prothrombin (PT) and activated partial thromboplastin time (aPTT) less than 1.5 times control",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the clinical situation is stabilized, laboratory studies are obtained less frequently.",
"   </p>",
"   <p>",
"    The optimal hemoglobin concentration for pregnant women who are about to deliver has not been determined and likely depends on patient specific factors, such as the expected blood loss during delivery, baseline hemoglobin level and rate of fall, and presence of medical comorbidities. The overall risk of mortality increases as the hemoglobin concentration decreases; some experts have suggested a minimum hemoglobin of 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for nonpregnant individuals undergoing surgical procedures associated with significant bleeding and for patients receiving massive transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Likewise, a consensus development conference on perioperative red cell transfusion concluded that cardiac output does not significantly decline until the hemoglobin concentration decreases to 7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/30\">",
"     30",
"    </a>",
"    ]. The United States Military Combat Trauma Units in Iraq use a hematocrit of 21 percent for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/31\">",
"     31",
"    </a>",
"    ]. At Parkland Hospital in Dallas, Texas, the goal in massive obstetrical hemorrhage is to maintain a hematocrit of 25 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/32\">",
"     32",
"    </a>",
"    ]. We also use a hematocrit target of 25 to 30 percent for initiating blood transfusion therapy because pregnant women with DIC have ongoing blood loss, which will further increase at the time of delivery, and because equilibration generally results in a fall in hematocrit. A lower hematocrit level is acceptable after the patient has delivered, is no longer actively bleeding, and is hemodynamically stable.",
"   </p>",
"   <p>",
"    A fibrinogen level &ge;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is considered the minimum level necessary for adequate coagulation, but &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is better. An observational study demonstrated that 100 percent of postpartum women who developed severe hemorrhage had fibrinogen levels &lt;200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    while 80 percent of those with fibrinogen &gt;400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    did not develop severe hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/33\">",
"     33",
"    </a>",
"    ]. Similar predictive data for platelet concentration are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Obstetrical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prenatal record should be reviewed, with particular attention to risk factors for DIC and comorbidities with the potential for severe sequelae from DIC (eg, placenta previa). Results of previous ultrasound examinations (eg, gestational age, fetal or placental abnormalities) should be reviewed, and electronic fetal heart rate and uterine contraction monitors should be applied. Ultrasound can be performed in the patient's labor room to evaluate fetal status, estimate gestational age or weight, and determine fetal presentation.",
"   </p>",
"   <p>",
"    Fetal viability and gestational age significantly impact management of the gravida with DIC. If an intrauterine fetal demise is identified or the fetus is clearly previable, then the entire focus becomes the optimal care of the mother. The limit of viability is defined as the stage of maturity that would ensure a reasonable chance of survival without severe deficits. Determining the limit of viability is desirable so that futile interventions that are costly and painful can be avoided in the infant who does not have a chance of reasonable outcome. However, deciding upon a threshold of viability is challenging, as it remains uncertain which extremely preterm infants, particularly those born at 23 and 24 weeks of gestation, have a reasonable chance of survival without severe deficits. The short- and long-term morbidity from prematurity, the intensity of care required, and likelihood of survival at various gestational ages are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the fetus is alive and at a viable gestational age, the fetal heart rate typically shows a nonreassuring pattern in pregnancies complicated by major bleeding, given that maternal hemodynamic instability results in poor placental perfusion and suboptimal fetal oxygenation. In these cases, the maternal and fetal risks and benefits of immediate delivery versus delaying delivery for treatment of coagulopathy need to be weighed. Involving the",
"    <span class=\"nowrap\">",
"     pediatrics/neonatology",
"    </span>",
"    and anesthesia services can help when discussing these issues with the patient or her legal guardians.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery is a key component in the management of undelivered women with DIC. Termination of pregnancy leads to resolution of the antepartum disorders that initiated DIC, such as abruptio placentae, hemorrhagic placenta previa, severe",
"    <span class=\"nowrap\">",
"     preeclampsia/HELLP,",
"    </span>",
"    intrauterine sepsis, and dead fetus syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21711045\">",
"    <span class=\"h2\">",
"     Patients with no contraindications to vaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the fetus is dead or has a very poor prognosis (eg, gestational age less than 23 to 24 weeks of gestation, lethal or life-threatening congenital abnormality, preterminal fetal heart rate tracing), the goal is minimizing maternal morbidity and mortality. In many but not all cases, this means avoiding operative delivery because of the risk of uncontrollable hemorrhage from surgical incisions and lacerations.",
"   </p>",
"   <p>",
"    The mother is supported with crystalloid and replacement of blood and blood products, and delivery is initiated. Delivery removes the trigger for DIC in obstetrical cases (placenta, septic products of conception) and causes the myometrium to contract (uterine involution), thus removing both the major source and site of hemorrhage. In the second trimester, dilation and extraction (D&amp;E) is a good option for rapid uterine evacuation if the physician is skilled in this procedure. In other cases, labor should be induced if it has not already ensued or augmented if it is not progressing rapidly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/35/1591?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis and management of stillbirth\", section on 'Second trimester (from about 18 weeks to 28 weeks of gestation)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/35/1591?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and management of stillbirth\", section on 'Third trimester'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the cervix is unfavorable, we use both a mechanical method of cervical ripening (balloon catheter, hygroscopic dilator) and a pharmacologic method of labor induction (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ). This procedure is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=see_link\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal delivery is not the safest maternal option if hemodynamic instability from ongoing brisk uterine bleeding persists despite vigorous transfusion of blood and blood products, or if the mother would be endangered by vaginal delivery, such as if she has a placenta previa. In these cases, cesarean delivery is indicated to save the mother's life. Cesarean delivery is also indicated if prompt delivery has the potential to reduce fetal morbidity and mortality (eg, viable fetus with malpresentation or nonreassuring fetal heart rate tracing).",
"   </p>",
"   <p>",
"    It is desirable, but not always possible, to correct or improve the clotting abnormality prior to cesarean delivery. A delay in operative intervention could lead to worsening of the coagulopathy, further blood loss, and, potentially, fetal death. On the other hand, immediate operative intervention in a woman with severe hypovolemia and DIC could prove fatal for the woman. If a cesarean has to be performed urgently, then red blood cells, fresh frozen plasma, platelets, and cryoprecipitate should be available in the operating room and administered if there is clinical or laboratory evidence of impaired coagulation. Persistent bleeding without clotting from incision and needle sites is a clinical sign of coagulopathy; fresh frozen plasma and cryoprecipitate should be given immediately, without waiting for the results of laboratory studies.",
"   </p>",
"   <p>",
"    One or more surgeons experienced in cesarean or puerperal hysterectomy, pelvic surgery, and management of pelvic hemorrhage should be involved in the surgical procedure. This may include a gynecologic oncologist, maternal fetal medicine specialist, obstetrician,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general surgeon. The pediatric staff should be notified that neonatal resuscitation of a potentially compromised newborn may be needed. If interventional radiologic services are available, they should be notified of the potential need for their services, as well.",
"   </p>",
"   <p>",
"    There are no data from randomized trials or controlled studies on which to base recommendations about surgical approach. These decisions are based on individual patient characteristics and the clinical experience of the surgeon. We prefer an infraumbilical vertical midline incision because it is fast, provides excellent exposure of both the upper and lower pelvis, and is less likely than a transverse incision to be complicated by a rectus sheath (subfascial) hematoma postpartum. After delivery of the fetus, we manually extract the placenta to hasten uterine involution. Uterotonic drugs are given and the hysterotomy incision is closed promptly to curtail bleeding.",
"   </p>",
"   <p>",
"    The obstetric, anesthetic and surgical team members should communicate with each other regarding the volume and rate of blood loss, site(s) of bleeding, quality of clot formation, and response to techniques used for control of postpartum hemorrhage. Several of these techniques (uterine vessel ligation, uterine compression sutures, balloon tamponade) are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27336?source=see_link\">",
"     \"Management of postpartum hemorrhage at cesarean delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If uterine bleeding remains brisk and maternal hemodynamic status is deteriorating despite initial surgical interventions and blood component replacement, we use a Penrose drain or urinary catheter as a uterine tourniquet. The drain is placed as low as possible around the lower uterine segment without incorporating the urinary bladder, and then the two ends are pulled in opposite directions and as tightly as possible around the corpus to mechanically occlude the vascular supply. The tourniquet can be held in place with a clamp. This procedure markedly reduces blood loss and allows time for the anesthesia team members to catch up with transfusion requirements. When the patient is hemodynamically stable, the tourniquet is removed and the surgical procedure is completed. The abdomen is closed in a standard fashion.",
"   </p>",
"   <p>",
"    There are limited available data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    sodium, synthetic protease inhibitor, antithrombin, human recombinant activated protein C, recombinant human soluble thrombomodulin, recombinant tissue factor pathway inhibitor, or recombinant activated factor VIIa for the treatment of DIC during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/34\">",
"     34",
"    </a>",
"    ]. No randomized trials have evaluated any of these hematologic interventions for treatment of DIC in",
"    <span class=\"nowrap\">",
"     pregnant/postpartum",
"    </span>",
"    women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/35\">",
"     35",
"    </a>",
"    ]. Among these interventions, we suggest human recombinant factor VIIa for patients who continue to bleed despite conventional treatment, but low levels of coagulation factors and cofactors may limit its effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/36\">",
"     36",
"    </a>",
"    ]; the plasma fibrinogen level should be &ge;50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/37\">",
"     37",
"    </a>",
"    ]. Although thrombosis is a potential complication, these events appear to be less common in obstetrical patients who receive recombinant factor VIIa than in other types of patients. The use of recombinant factor VIIa, including associated risks, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Recombinant activated factor VII'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=see_link\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hysterectomy is a last resort in women who wish to preserve childbearing capacity, but should be initiated earlier rather than later when future pregnancy is not planned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29367?source=see_link\">",
"     \"Peripartum hysterectomy\"",
"    </a>",
"    .) Delaying hysterectomy increases blood loss and frequency of complications. Moreover, significant hemorrhage is more likely with emergency hysterectomy than with elective hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients will continue to bleed despite these measures and can enter a lethal downward spiral characterized by hypothermia, coagulopathy, and metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/39\">",
"     39",
"    </a>",
"    ]. Criteria proposed for this \"in extremis\" state include pH &lt;7.30, temperature &lt;35 degrees Celsius, combined resuscitation and procedural time &gt;90 minutes, non-mechanical bleeding, and transfusion requirement &gt;10 units packed RBCs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/40\">",
"     40",
"    </a>",
"    ]. To abort the cycle, the bleeding area can be tightly packed using a pelvic pressure pack or lap sponges [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/41\">",
"     41",
"    </a>",
"    ]. The abdominal wound, including the fascia, is left open and a pressure dressing is applied. We have also used towel clips to temporarily reapproximate the",
"    <span class=\"nowrap\">",
"     skin/subcutaneous",
"    </span>",
"    tissue.",
"   </p>",
"   <p>",
"    The patient is transferred to an intensive care unit for continuous monitoring, replacement of appropriate blood products, broad spectrum antimicrobials, and correction of physiologic derangements (\"damage control\") [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15961/abstract/40\">",
"     40",
"    </a>",
"    ]. The need for &ge;2 units packed RBCs per hour for three hours is a sign of significant ongoing bleeding and need for surgical intervention or arterial embolization by an interventional radiologist. Otherwise, when the patient is stable, she is returned to the operating room to undergo definitive surgical care. This approach halts the downward spiral and lessens the risk of abdominal compartment syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/62/994?source=see_link\">",
"       \"Patient information: Disseminated intravascular coagulation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstetrical disorders that may initiate disseminated intravascular coagulation (DIC) include abruptio placentae, severe hemorrhage, HELLP",
"      <span class=\"nowrap\">",
"       syndrome/eclampsia/severe",
"      </span>",
"      preeclampsia, amniotic fluid embolism, acute fatty liver of pregnancy, septic abortion, and dead fetus syndrome. (See",
"      <a class=\"local\" href=\"#H1949821\">",
"       'Pregnancy complications that may lead to DIC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Placental disorders can cause DIC because trophoblast cells strongly express tissue factor, which is important in the production of thrombin. Uncontrolled production of thrombin results in widespread intravascular fibrin deposition, widespread fibrinolysis, and hemorrhage, with further depletion of coagulation factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology and pathogenesis of DIC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of DIC is based on the presence of typical clinical features (bleeding, shock, respiratory distress, renal failure) supported by laboratory findings of coagulopathy. (See",
"      <a class=\"local\" href=\"#H1950009\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1960559\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The key elements in managing the pregnant woman with DIC are to identify and treat the underlying disorder and provide supportive care, particularly replacement of blood products. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial steps in evaluation and support of the pregnant woman in DIC are: inform the blood bank, anesthesia, and pediatric services; insert two large bore intravenous catheters; keep oxygen saturation &gt;95 percent; identify and eliminate the triggering event; monitor vital signs and blood loss; and avoid hypothermia.",
"      <br/>",
"      <br/>",
"      We type and cross match a minimum of 6 units packed red blood cells, 6 units fresh frozen plasma, 10 bags of cryoprecipitate and 1 six-pack of platelets, and begin transfusion of blood products prior to getting initial laboratory results back. We suggest transfusion of red blood cells, fresh frozen plasma and platelets in a ratio of 1:1:1 in cases of severe DIC. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Initial steps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The key points in obstetrical evaluation are review of the prenatal record, with particular attention to risk factors for DIC and comorbidities with potentially severe sequelae from DIC (eg, placenta previa); establishment of gestational age, determining whether fetal or placental abnormalities are present; and assessment of the fetal heart rate pattern and uterine contractions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Obstetrical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We draw laboratory studies every 30 minutes to guide blood product replacement, and we transfuse blood products to achieve the following minimum levels for delivery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Follow-up laboratory tests and transfusion targets'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &ge;50,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Fibrinogen &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Prothrombin (PT) and partial thromboplastin time (PTT) less than 1.5 times control",
"     </li>",
"     <li>",
"      Hematocrit 25 to 30 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the fetus is nonviable, the goal is minimizing maternal morbidity and mortality. In the second trimester, we suggest dilatation and extraction, if physicians skilled in performing this procedure are available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Otherwise, in most cases, we favor supporting the mother with crystalloid and replacement of blood and blood products, and inducing or augmenting labor. (See",
"      <a class=\"local\" href=\"#H21711045\">",
"       'Patients with no contraindications to vaginal delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to standard indications for cesarean delivery, a cesarean is indicated if hemodynamic instability from ongoing brisk uterine bleeding persists despite vigorous transfusion of blood and blood products. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is desirable, but not always possible, to correct the bleeding diathesis prior to surgery. If a cesarean has to be performed urgently, then packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate should be available in the operating room and administered if there is clinical or laboratory evidence of impaired coagulation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For uterine bleeding that persists despite standard measures, we suggest using a Penrose drain or urinary catheter as a uterine tourniquet. This procedure markedly reduces blood loss and allows time for the anesthesia team members to catch up with transfusion requirements. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even though hysterectomy is considered a last resort in women who wish to preserve childbearing capacity, it should be performed promptly if continued bleeding persists despite other preventive measures. These women can enter a lethal downward spiral characterized by hypothermia, coagulopathy, and metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If hysterectomy is not performed, the bleeding area is tightly packed and the wound dressed, but left open, and the patient is transferred to an intensive care unit for continuous monitoring, replacement of appropriate blood products, and correction of physiologic derangements. When stable, she is returned to the operating room to undergo definitive surgical care. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cesarean delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/1\">",
"      DeLee, JB. A case of fatal hemorrhagic diathesis, with premature detachment of the placenta. Am J Obstet Dis Women Child 1901; 44:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/2\">",
"      Levi M. Disseminated intravascular coagulation (DIC) in pregnancy and the peri-partum period. Thromb Res 2009; 123 Suppl 2:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/3\">",
"      Callaghan WM, Creanga AA, Kuklina EV. Severe maternal morbidity among delivery and postpartum hospitalizations in the United States. Obstet Gynecol 2012; 120:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/4\">",
"      Thachil J, Toh CH. Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. Blood Rev 2009; 23:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/5\">",
"      PRITCHARD JA. Fetal death in utero. Obstet Gynecol 1959; 14:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/6\">",
"      Gando S. Microvascular thrombosis and multiple organ dysfunction syndrome. Crit Care Med 2010; 38:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/7\">",
"      Montagnana M, Franchi M, Danese E, et al. Disseminated intravascular coagulation in obstetric and gynecologic disorders. Semin Thromb Hemost 2010; 36:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/8\">",
"      Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999; 82:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/9\">",
"      Gerbasi FR, Bottoms S, Farag A, Mammen E. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/10\">",
"      Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/11\">",
"      Toh CH, Hoots WK, SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007; 5:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/12\">",
"      Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/13\">",
"      Gando S, Iba T, Eguchi Y, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006; 34:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/14\">",
"      Sperry JL, Ochoa JB, Gunn SR, et al. An FFP:PRBC transfusion ratio &gt;/=1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma 2008; 65:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/15\">",
"      Duchesne JC, Islam TM, Stuke L, et al. Hemostatic resuscitation during surgery improves survival in patients with traumatic-induced coagulopathy. J Trauma 2009; 67:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/16\">",
"      Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007; 62:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/17\">",
"      Cinat ME, Wallace WC, Nastanski F, et al. Improved survival following massive transfusion in patients who have undergone trauma. Arch Surg 1999; 134:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/18\">",
"      Gunter OL Jr, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma 2008; 65:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/19\">",
"      Duchesne JC, Hunt JP, Wahl G, et al. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? J Trauma 2008; 65:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/20\">",
"      Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/21\">",
"      Moore FA, Nelson T, McKinley BA, et al. Is there a role for aggressive use of fresh frozen plasma in massive transfusion of civilian trauma patients? Am J Surg 2008; 196:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/22\">",
"      Teixeira PG, Inaba K, Shulman I, et al. Impact of plasma transfusion in massively transfused trauma patients. J Trauma 2009; 66:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/23\">",
"      Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma 2009; 66:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/24\">",
"      Shaz BH, Dente CJ, Nicholas J, et al. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion 2010; 50:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/25\">",
"      Bell SF, Rayment R, Collins PW, Collis RE. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth 2010; 19:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/26\">",
"      POE MF. Clot observation test for clinical diagnosis of clotting defects. Anesthesiology 1959; 20:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/27\">",
"      Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet 1996; 348:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/28\">",
"      Carson JL, Poses RM, Spence RK, Bonavita G. Severity of anaemia and operative mortality and morbidity. Lancet 1988; 1:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/29\">",
"      Burtelow M, Riley E, Druzin M, et al. How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol. Transfusion 2007; 47:1564.",
"     </a>",
"    </li>",
"    <li>",
"     Consensus Development Conference: Perioperative red cell transfusion. Vol. 7, No. 4, National Institutes of Health, Bethesda, MD 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/31\">",
"      Barbieri, RL. Control of massive hemorrhage: Lessons from Irag reach the U.S.labor and delivery suite. OBG Management 2007; 19:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/32\">",
"      Alexander JM, Sarode R, McIntire DD, et al. Whole blood in the management of hypovolemia due to obstetric hemorrhage. Obstet Gynecol 2009; 113:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/33\">",
"      Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/34\">",
"      Mart&iacute;-Carvajal AJ, Comuni&aacute;n-Carrasco G, Pe&ntilde;a-Mart&iacute; GE. Haematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum. Cochrane Database Syst Rev 2011; :CD008577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/35\">",
"      Kobayashi A, Matsuda Y, Mitani M, et al. Assessment of the usefulness of antithrombin-III in the management of disseminated intravascular coagulation in obstetrically Ill patients. Clin Appl Thromb Hemost 2010; 16:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/36\">",
"      Sobieszczyk S, Breborowicz GH, Platicanov V, et al. Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstet Gynecol Scand 2006; 85:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/37\">",
"      Lewis NR, Brunker P, Lemire SJ, Kaufman RM. Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. Transfusion 2009; 49:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/38\">",
"      Chestnut DH, Dewan DM, Redick LF, et al. Anesthetic management for obstetric hysterectomy: a multi-institutional study. Anesthesiology 1989; 70:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/39\">",
"      Rotondo MF, Zonies DH. The damage control sequence and underlying logic. Surg Clin North Am 1997; 77:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/40\">",
"      Sagraves SG, Toschlog EA, Rotondo MF. Damage control surgery--the intensivist's role. J Intensive Care Med 2006; 21:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15961/abstract/41\">",
"      Dildy GA, Scott JR, Saffer CS, Belfort MA. An effective pressure pack for severe pelvic hemorrhage. Obstet Gynecol 2006; 108:1222.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4460 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-1E842E28B5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15961=[""].join("\n");
var outline_f15_37_15961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1949821\">",
"      PREGNANCY COMPLICATIONS THAT MAY LEAD TO DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY AND PATHOGENESIS OF DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1950009\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1960559\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Initial steps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Follow-up laboratory tests and transfusion targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Obstetrical evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT OF DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21711045\">",
"      Patients with no contraindications to vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4460\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4460|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/4/32846\" title=\"algorithm 1\">",
"      Pathophysiology of DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4460|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/28/8652\" title=\"table 1\">",
"      Major causes of DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/33/38424\" title=\"table 2\">",
"      Normal reference ranges in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/5/33886\" title=\"table 3\">",
"      Massive transfusion protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/3/42043\" title=\"table 4\">",
"      Blood replacement products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/35/1591?source=related_link\">",
"      Diagnosis and management of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21703?source=related_link\">",
"      Hematologic changes in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=related_link\">",
"      Limit of viability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42952?source=related_link\">",
"      Management of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27336?source=related_link\">",
"      Management of postpartum hemorrhage at cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/62/994?source=related_link\">",
"      Patient information: Disseminated intravascular coagulation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29367?source=related_link\">",
"      Peripartum hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34663?source=related_link\">",
"      Placental abruption: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/49/2841?source=related_link\">",
"      Spontaneous abortion: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=related_link\">",
"      Techniques for ripening the unfavorable cervix prior to induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_37_15962="Management and prognosis of cerebral palsy";
var content_f15_37_15962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and prognosis of cerebral palsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15962/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15962/contributors\">",
"     Geoffrey Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15962/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15962/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15962/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/37/15962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/37/15962/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/37/15962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral palsy (CP) consists of a heterogeneous group of nonprogressive clinical syndromes that are characterized by motor and postural dysfunction. These conditions, which range in severity, are due to abnormalities of the developing brain resulting from a variety of causes. Although the disorder itself is not progressive, the appearance of neuropathologic lesions and their clinical expression may change over time as the brain matures.",
"   </p>",
"   <p>",
"    The management and prognosis of CP are reviewed here. The epidemiology, etiology, clinical manifestations, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"     \"Clinical features of cerebral palsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4104?source=see_link\">",
"     \"Diagnosis and classification of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT GOALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychological development, communication, and education are priorities in the management of CP. Longitudinal social, language, and psychometric assessment provides a rational basis for training in communication and activities of daily living and allows the child to derive the maximum benefit from school [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As the child becomes older, assessment and training for a potential occupation become important (",
"    <a class=\"graphic graphic_table graphicRef60793 \" href=\"UTD.htm?7/24/7563\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Interventions for CP should be directed at maximizing the quality of life by improvement in daily function and reduction of the extent of disability. Initially, the parents and other caregivers should learn how to seat, dress, feed, communicate with, transfer, transport, and toilet the child [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/3\">",
"     3",
"    </a>",
"    ]. With growth and development, the child should achieve maximal independence in these activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Multidisciplinary team",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the child with CP requires a multidisciplinary team to address the multiple medical, social, psychological, educational, and therapeutic needs. Team members should have a goal-oriented approach that is based upon an adequate knowledge base and an understanding and appreciation of contributions from all the disciplines. Management should be directed at promoting the child's:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Social and emotional development",
"     </li>",
"     <li>",
"      Communication",
"     </li>",
"     <li>",
"      Education",
"     </li>",
"     <li>",
"      Nutrition",
"     </li>",
"     <li>",
"      Mobility",
"     </li>",
"     <li>",
"      Maximal independence in activities of daily living",
"     </li>",
"     <li>",
"      Appearance as nearly normal as possible",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The team should set functional goals for the child that are realistic and periodically reevaluated. The aim of these goals is for the child to achieve maximal potential in all areas of development and promote independence. Participation of the principal care givers and teachers in treatment sessions is essential. It should be recognized that different areas of development are interdependent. It is important to address the emotional and recreational needs of the child and parents, as well as treating physical aspects of the disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPASTICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery may help to reduce spasticity, hyperreflexia, and clonus, although they do not improve weakness and incoordination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Furthermore, whether these interventions improve functional outcomes is uncertain.",
"   </p>",
"   <p>",
"    For medical therapy of spasticity, there is stronger evidence to support the use of botulinum toxin than there is for oral antispastic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/6\">",
"     6",
"    </a>",
"    ]. The evidence and clinical use of each approach is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Botulinum toxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection of botulinum toxin type A (BTX A) into affected muscles blocks the presynaptic release of acetylcholine from motor endplates of the lower motor neuron at the myoneural junction and decreases tone by limiting muscle contraction. Case series, open label studies, and clinical trials suggest that BTX A temporarily reduces spasticity and either lengthens or delays the shortening of affected muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/6-14\">",
"     6-14",
"    </a>",
"    ]. A preponderance of evidence also suggests that BTX A in combination with occupational therapy improves some functional outcomes in addition to spasticity, although it may not improve gait [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. Most reports suggest that the drug is generally safe, but there have been case reports of life-threatening systemic toxicity. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Complications'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study, 125 children (mean age 5.2 years) with dynamic equinus spasticity during walking were randomly assigned to one of three doses of BTX A (10, 20, or 30",
"    <span class=\"nowrap\">",
"     units/kg)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/12\">",
"     12",
"    </a>",
"    ]. The dynamic component of gastrocnemius shortening was significantly decreased and maximum active gastrocnemius length increased in all treated groups after four weeks.",
"   </p>",
"   <p>",
"    Investigators hypothesized that, in addition to reducing tone, early treatment may modify the effect of spasticity on bone and soft tissue and reduce the extent of later surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, one long-term study (median length of treatment 18 months) showed effects on muscle tone after each injection, but gradual deterioration in range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/19\">",
"     19",
"    </a>",
"    ]. The study did not include a control group, so it is unclear whether the range of motion deteriorated faster or slower than patients who were not treated with BTX A. These observations suggest that long-term treatment with BTX A is not necessarily effective in preventing contractures, and raises the possibility that it could even contribute to contracture formation.",
"   </p>",
"   <p>",
"    A randomized placebo-controlled trial showed no difference in the family's satisfaction with the child's function, despite documentation of improvement in spasticity and function in the botulinum-treated group, using a variety of objective measures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/20\">",
"     20",
"    </a>",
"    ]. These observations suggest that treatment benefits may be subtle, and that providers should communicate realistic expectations to the family prior to embarking on treatment.",
"   </p>",
"   <p>",
"    BTX A is used primarily in calf muscles to treat dynamic equinus of the ankle in patients with diplegia or hemiplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/21\">",
"     21",
"    </a>",
"    ]. It is injected into several areas of the muscle. Injections must be repeated every three to eight months to maintain the effect. Three to ten percent of adults develop neutralizing antibodies to the toxin after repeated injections and no longer benefit from treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A two-year trial in children did not detect a cumulative or persisting effect with serial BTX A injections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/24\">",
"     24",
"    </a>",
"    ]. This study also did not detect a waning effect of serial treatment, but neutralizing antibodies were not measured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appropriate use of BTX A in children with CP has been described in a treatment protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/25\">",
"     25",
"    </a>",
"    ]. BTX A is indicated in patients who have increased muscle tone that interferes with function or is likely to lead to joint contracture with growth; the best evidence is for equinus varus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/6,26-28\">",
"     6,26-28",
"    </a>",
"    ]. Patients younger than four years old and without fixed contractures are expected to have the most favorable response. Ideally, only two or three muscles will require treatment at one time.",
"   </p>",
"   <p>",
"    In general, BTX A should NOT be used in children younger than 18 months old because no data are available on the long-term use of this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/25\">",
"     25",
"    </a>",
"    ]. BTX A is not appropriate for patients with diffuse hypertonia, although it might be used to treat focal aspects of generalized spasticity. Fixed contractures are not amenable to BTX therapy, although BTX A injections may facilitate serial casting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to therapy, a complete baseline assessment should be performed by a multidisciplinary team [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/25\">",
"     25",
"    </a>",
"    ]. The evaluation should include range of motion, strength, assessment of selective motor control, muscle tone, and function. Treatment goals should be specified and subsequent evaluation should assess whether these have been met.",
"   </p>",
"   <p>",
"    Dosing guidelines have been developed for specific muscles and are based upon body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/25\">",
"     25",
"    </a>",
"    ]. No reliable potency standard has been established for BTX A, and the biological effects vary greatly among preparations from different manufacturers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/26\">",
"     26",
"    </a>",
"    ]. As a result, the different BTX A preparations (abotulinumtoxinA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/18/295?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    ) and should not be used interchangeably, and separate dosing schemes must be established for each. Adjustments are also made based upon factors including the patient's weight, muscle bulk, the number of muscles being injected simultaneously, and the response to previous therapy. The patient should be reevaluated six weeks after treatment. The effect typically lasts three to eight months, after which treatment can be repeated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are rare and include fever, which may last for one to three days, and transient pain, local irritation, and bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/25\">",
"     25",
"    </a>",
"    ]. Weakness and temporary (less than two weeks) loss of function in the injected area may follow a dose that is too high, and may indicate previously undiagnosed muscle weakness. A two-year treatment trial detected no excess adverse events among children treated with BTX A as compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Food and Drug Administration has issued a warning about the possibility of life-threatening systemic adverse effects from local botulinum toxin injections. The warning was based on reports of severe difficulty swallowing or breathing in several patients and occurred mostly in children with cerebral palsy receiving local injections for limb spasticity. Some of these complications appear be caused by inadvertent overdosing, because potency determinations expressed in \"units\" varied among botulinum toxin products. In response, the FDA mandated changes in drug names, designed to emphasize these differences in drug potency and prevent medication errors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/29\">",
"     29",
"    </a>",
"    ]. Providers should be alert for the potential of systemic effects, including dysphagia, dysphonia, weakness, or dyspnea, occurring up to several weeks after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oral antispastic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43335?source=see_link\">",
"     Dantrolene",
"    </a>",
"    , benzodiazepines, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    have been used by some clinicians to treat spasticity in CP, although I do not find these as useful as botulinum toxin. This view is supported by findings of a systematic review published in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/30\">",
"     30",
"    </a>",
"    ]. The review concluded that evidence regarding effectiveness of these drugs is scarce and weak. Only 12 double blind trials with a total of 469 patients met criteria for inclusion. The general methodological quality of these studies was poor. In addition, most studies were of small size and short treatment duration; the magnitude of the therapeutic effect was described in only four studies and it was small. Only three of the included trials tested antispastic drugs in patients with cerebral palsy, one with baclofen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/31\">",
"     31",
"    </a>",
"    ], and two with dantrolene [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Dantrolene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/20/43335?source=see_link\">",
"     Dantrolene",
"    </a>",
"    sodium reduces muscle contraction by inhibiting release of calcium ions from the sarcoplasmic reticulum. Treatment may decrease tone, tendon reflexes, and scissoring and may improve range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/32\">",
"     32",
"    </a>",
"    ], but objective functional improvement is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/33\">",
"     33",
"    </a>",
"    ]. Side effects, which are common, include weakness, drowsiness, lethargy, paresthesias, nausea, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/34\">",
"     34",
"    </a>",
"    ]. The use of this drug may be limited by hepatic toxicity, which occurred in 1.8 percent of 1044 patients treated for at least 60 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/35\">",
"     35",
"    </a>",
"    ]. When additional cases of dantrolene-associated hepatic disease reported after marketing of the drug were included in the analysis, the case fatality rate of 50 cases was 28 percent. Liver disease resolved in the remainder after discontinuation of the drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    reduce spasticity. The mechanism is increased presynaptic inhibition due to binding to benzodiazepine receptors that are linked to receptors for the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) located on the terminals of primary afferent fibers; there is subsequent increased affinity for GABA at the receptor site and increased flux of chloride ions across the terminal membrane.",
"   </p>",
"   <p>",
"    Studies of moderate quality suggest that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    is probably effective for the short-term treatment of spasticity in children with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/6,36\">",
"     6,36",
"    </a>",
"    ]. The tranquilizer effect makes benzodiazepines useful in dyskinetic CP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/37\">",
"     37",
"    </a>",
"    ]. However, they may produce sedation, weakness, ataxia, memory disturbances, and dependence after prolonged use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     Baclofen",
"    </a>",
"    , an analog of GABA, binds to the GABA-B receptors on the terminals of primary afferent fibers. Activation of these receptors inhibits the influx of calcium ions into presynaptic terminals and suppresses release of excitatory neurotransmitters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/37\">",
"     37",
"    </a>",
"    ]. This inhibits monosynaptic and polysynaptic reflexes and reduces gamma efferent activity.",
"   </p>",
"   <p>",
"    Limited evidence from two small randomized trials in children with CP suggested that oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    results in modest improvement of spasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/31,38\">",
"     31,38",
"    </a>",
"    ]. Side effects are common, and include confusion, sedation, hypotonia, ataxia, paresthesias, and nausea. Seizures and hallucination may occur if the drug is discontinued abruptly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intrathecal baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    is limited because poor lipid solubility results in low cerebrospinal fluid (CSF) levels. Intrathecal baclofen (administered via a pump) achieves higher CSF drug levels. Low-quality evidence suggests that the treatment may be effective in reducing spasticity in severely affected patients, but probably is not helpful in more mildly affected (ambulant) patients; its use is also associated with substantial complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/6,40,41\">",
"     6,40,41",
"    </a>",
"    ]. Therefore, this treatment is generally restricted to severely affected patients. Guidelines for determining the optimal dose and placement of the catheter tip have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, continuous intrathecal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    infusion reduced spasticity in the upper and lower extremities and improved upper extremity function and activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/43\">",
"     43",
"    </a>",
"    ]. Athetosis was not improved. Complications related to the catheter occurred in 20 percent of patients, and 5 percent had infection requiring pump removal. Side effects include confusion and lethargy and appear to be related to the dose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another larger study of intrathecal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    showed similar improvement in spasticity but a high rate of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/45\">",
"     45",
"    </a>",
"    ]. Within two months of insertion of the pump, 50 percent of patients had adverse events that were potentially related to treatment; the two most common were lethargy and hypotonia. Common surgical complications included problems related to the catheter, seromas, and cerebrospinal fluid leak.",
"   </p>",
"   <p>",
"    A case series described successful treatment of 35 children with severe CP, treated with a continuous infusion of intrathecal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7878?source=see_link\">",
"     baclofen",
"    </a>",
"    for 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/46\">",
"     46",
"    </a>",
"    ]. The patients experienced early improvement in pain and sleep, and later improvement in social function and mobility. Treatment was stopped in three additional patients because of agitation or infection. Another study described the effects of intrathecal baclofen for 18 months in children with severe CP, using a group awaiting treatment as controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/47\">",
"     47",
"    </a>",
"    ]. Children treated with intrathecal baclofen had reduced tone and spasms and improved perceived comfort and ease of nursing care. The main side effect was increased constipation. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment of spasticity includes selective dorsal rhizotomy and stereotactic encephalotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Selective dorsal rhizotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective dorsal rhizotomy (SDR) is a surgical procedure that selectively divides parts of the dorsal lumbosacral roots of the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/21\">",
"     21",
"    </a>",
"    ]. This interrupts the afferent limb of the reflex arc on the sensory side, thus reducing spasticity without causing paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/7\">",
"     7",
"    </a>",
"    ]. This technique may provide a small gain in function.",
"   </p>",
"   <p>",
"    A meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/48\">",
"     48",
"    </a>",
"    ] evaluated outcomes of three randomized controlled trials of SDR plus physiotherapy (PT) compared to PT alone in a total of 90 children (82 younger than eight years of age) with spastic diplegia who were primarily ambulatory [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Spasticity at nine to 12 months (assessed by the Ashworth scale) was significantly less with SDR plus PT compared to PT alone. The SDR group had a modest but significant improvement in function (assessed by the Gross Motor Function Measure) and this correlated with the proportion of dorsal root tissue that was transected. No serious adverse events were reported.",
"   </p>",
"   <p>",
"    Long term outcomes of SDR are available for case series, but not controlled trials. In one series of 93 children with spastic CP who had SDR accompanied by intraoperative electrophysiologic monitoring and were evaluated at six months and at one, three, and five years, postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/52\">",
"     52",
"    </a>",
"    ]. Spasticity, range of motion, and functional muscle strength improved one year after the procedure and continued to improve through five years. Lower extremity motor function showed the greatest improvement. Patients showed sustained improvement in alignment and postural stability and their ability to perform difficult transitional movements was increased.",
"   </p>",
"   <p>",
"    Which children are most likely to benefit from SDR is uncertain. I recommend the procedure in severely affected nonambulatory patients with contractures. In these children, SDR aids in cleanliness and dressing. Other providers have applied this technique to children with substantially higher levels of physical function, with long-term benefits to gait abnormalities as measured by instrumented gait analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/53\">",
"     53",
"    </a>",
"    ]. However, controlled evidence-based criteria for patient selection, and the clinical benefit compared to risks, remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Stereotactic encephalotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic encephalotomy on the basal ganglia (cutting specific tracts) has been performed in patients with hyperkinesia or dystonia. In a retrospective study, improvement was seen in eight of 18 patients (initial sample was 28 patients) evaluated at an average of 21 years after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/54\">",
"     54",
"    </a>",
"    ]. Outcomes were better in patients with hyperkinesia, tremor, and predominantly unilateral dystonia. This procedure may be considered in children with very severe dystonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ORTHOPEDIC INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthopedic interventions are directed at relief and prevention of deformity and maximizing function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Gait analysis, using physical examination, electromyography, and videotaping of limb motion, is often used to identify which muscles might benefit from lengthening procedures and to evaluate the effects of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. This should be performed when the gait is mature, usually between six and ten years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Muscle-tendon surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Release or recession of limb muscles and tendons (muscle-tendon surgery) is sometimes performed to reduce restricted joint motion or malalignment. They are recommended when fixed contractures interfere with possible function or care.",
"   </p>",
"   <p>",
"    These procedures result in small improvements in gait function. As an example, one study prospectively evaluated the effect of muscle-tendon surgery in 30 patients with spastic diplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/61\">",
"     61",
"    </a>",
"    ]. Operations were performed at a mean age of 8.7 years. Gait velocity and stride length increased by 25 and 18 percent over preoperative values, respectively, nine months after surgery and were maintained for two years. However, the Gross Motor Function Measure score changed little after surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hip disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of the hip, including subluxation, dislocation, and dislocation with degeneration and pain are common complications of spastic CP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/62\">",
"     62",
"    </a>",
"    ]. Although the hip is initially normal, progressive dysplasia results from a combination of bony deformity and muscle imbalance, usually involving the adductor and iliopsoas muscles.",
"   </p>",
"   <p>",
"    Diagnosis is made by an anteroposterior radiograph of the pelvis because physical examination is unreliable. Because earlier surgical intervention is associated with better outcomes, some clinicians recommend screening radiographic examination in all nonambulatory children with bilateral CP, beginning at 18 months of age and repeated every six to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postural management may have a role in prevention of hip dysplasia. In one retrospective study of 59 children with bilateral CP, use of 24 hour postural management in lying, sitting, and standing positions with the Chailey Adjustable Postural Support systems prior to the development of hip dysplasia was associated with maintenance of significantly more hip integrity than lower levels of postural support [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When hip subluxation is detected, soft-tissue lengthening is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/62\">",
"     62",
"    </a>",
"    ]. Comprehensive hip reconstruction can be performed in children younger than four years old who are more severely affected but have not developed advanced degenerative changes of the femoral head.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PHYSICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical therapy is an established part of treatment programs for cerebral palsy (CP) and is an integral and vital part of management. Although its effectiveness in promoting physical function is uncertain, physical therapy has an important role in supporting and encouraging caretakers to learn how best to handle, toilet, wash and feed their children with CP and to promote posture, mobility, and transfer. Physical therapy is typically started early and continued by the parents at home [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/25\">",
"     25",
"    </a>",
"    ]. Interventions attempt to reduce muscle tone.",
"   </p>",
"   <p>",
"    Despite a firm theoretical basis for using physical therapy, clinical studies have not established its effectiveness on physical function. As an example, in one study, 48 infants with mild to severe spastic diplegia who were 12 to 19 months of age were randomly assigned to receive 12 months of physical therapy or six months of infant stimulation (motor, sensory, language, and cognitive activities of increasing complexity) followed by six months of physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/65\">",
"     65",
"    </a>",
"    ]. After six months, infants treated with physical therapy had significantly lower mean motor quotient (49.1 versus 58.1) and were less likely to walk (12 versus 35 percent) as compared with infants who received stimulation. Significant differences persisted after 12 months. The incidence of contractures and the need for bracing or orthopedic surgery were similar. Treadmill interventions have been used to promote ambulatory function in young children, but this approach has been insufficiently studied to determine its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49061679\">",
"    <span class=\"h1\">",
"     OTHER INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other interventions have been used in attempts to improve motor function in cerebral palsy (CP). For each of the following interventions, there is little or no evidence to support a beneficial effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Constraint therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constraint-induced movement therapy (CIMT) has been used as a treatment for children with hemiplegic cerebral palsy. Children with hemiplegia avoid using the affected limb, in a process termed \"developmental disregard\". CIMT aims to promote function of the affected limb by encouraging its use through intermittent restraint of the unaffected limb during therapeutic tasks. The method of restraint varies from holding a child's hand to casting, and the length of time in the restraint varies from 1 to 24 hours a day. \"Forced use\" is a variation of CIMT in which the limb's use is encouraged only by placement of the contralateral restraint; no additional therapeutic tasks are assigned to the affected limb.",
"   </p>",
"   <p>",
"    Little experimental evidence is available to evaluate the efficacy of CIMT. Among three small controlled trials, there were trends supporting a treatment effect, one of which was statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Because the methods and outcomes used varied considerably among these trials, it is unclear which techniques, if any, are clinically useful [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Electrical stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical stimulation has been used in an effort to increase muscle strength in children with cerebral palsy. In neuromuscular electrical stimulation (NMES), electrical impulses of high intensity and short duration generate muscle contraction. In threshold electrical stimulation (TES), the stimulus is of lower intensity and does not generate muscle contraction; it is typically applied during sleep.",
"   </p>",
"   <p>",
"    While these approaches are appealing, several randomized trials have failed to show clinically significant improvement in muscle strength or function, although the numbers are small in these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12930776\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperbaric oxygen therapy was proposed as a treatment for CP based on the hypothesis that it might help to repair damage in the central nervous system. The technique was studied in two well-designed randomized trials, which failed to show any effect of hyperbaric oxygen treatment. These studies evaluated the effect of an eight-week course of hyperbaric oxygen treatment in school-aged children with CP. No effects were seen on standardized measures of gross motor function, attention, memory, or functional skills [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FEEDING DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feeding problems and oromotor dysfunction are common in children with CP [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. In a review of 49 children with CP, ages 12 to 72 months, more than 90 percent had clinically significant oromotor dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/77\">",
"     77",
"    </a>",
"    ]. Problems with sucking and swallowing occurred during the first year after birth in 57 and 38 percent, respectively. In a study of school-aged children with CP, common problems were need for help with feeding (89 percent), choking with food (56 percent), prolonged feeding time (&gt;3",
"    <span class=\"nowrap\">",
"     hours/day,",
"    </span>",
"    28 percent), and frequent vomiting (22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/79\">",
"     79",
"    </a>",
"    ]. These difficulties require caregivers to devote substantial time to oral feeding. Some children may not achieve sufficient intake if the time available for feeding is limited.",
"   </p>",
"   <p>",
"    Problems with feeding and nutrition influence morbidity and mortality in severe CP because of poor nutrition or chronic aspiration and lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/7,80\">",
"     7,80",
"    </a>",
"    ]. Aspiration events may or may not be associated with choking [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/81\">",
"     81",
"    </a>",
"    ]. Thus, severely disabled children require regular assessments of feeding skills and nutritional status, including weight and stature [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. In patients with growth failure or chronic aspiration, alternative feeding methods should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=see_link\">",
"     \"Enteral nutrition in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6045874\">",
"    <span class=\"h2\">",
"     Evaluation and growth charts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth charts specific to cerebral palsy have been developed and are available through this link: (",
"    <a class=\"external\" href=\"file://www.lifeexpectancy.org/articles/newgrowthcharts.shtml\">",
"     www.lifeexpectancy.org/articles/newgrowthcharts.shtm",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/84\">",
"     84",
"    </a>",
"    ]. These charts use weight-for-age (not weight-for-height) to measure nutritional status. Separate growth charts are used for children in each of five levels of CP severity, as defined by the Gross Motor Function Classification System (GMFCS). Each chart defines a weight threshold below which the child has an increased risk of morbidity and mortality. &nbsp;",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://motorgrowth.canchild.ca/en/GMFCS/resources/GMFCS-ER.pdf\">",
"     GMFCS",
"    </a>",
"    categorizes a patients&rsquo; motor function after six years of age as follows (modified descriptions of these categories are used for younger age groups):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level I &ndash; Walks without limitations",
"     </li>",
"     <li>",
"      Level II &ndash; Walks with limitations",
"     </li>",
"     <li>",
"      Level III &ndash; Walks using a hand-held mobility device (canes, crutches and anterior and posterior walkers that do not support the trunk)",
"     </li>",
"     <li>",
"      Level IV &ndash; Self-mobility with limitations; may use powered mobility",
"     </li>",
"     <li>",
"      Level V &ndash; Transported in a manual wheelchair",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because a causal association has not been established, it is not known whether intervention to maintain a child&rsquo;s weight above this threshold can decrease morbidity and mortality. Despite this limitation, patients with weights below this threshold should undergo a nutritional evaluation, including evaluation of caloric intake and exploration of alternative explanations for low body weight, such as familial short stature. If under-nutrition is confirmed, we suggest concerted efforts to boost nutrition through oral supplements or enteral feeds.",
"   </p>",
"   <p>",
"    Gastrostomy feeding improves nutritional status in children with CP and growth failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. This intervention also reduces aspiration and provides a reliable route for medication. It improves the quality of life for both the child and family in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/89\">",
"     89",
"    </a>",
"    ]. However, it is unknown whether gastrostomy placement prior to the development of malnutrition or aspiration pneumonia would improve long-term outcome in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, the optimal timing for this intervention remains uncertain. In addition, gastrostomy feedings for children with cerebral palsy may lead to excessive accumulation of adipose tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/90\">",
"     90",
"    </a>",
"    ]. Caloric goals should be modest because these children may have reduced energy needs. The evaluation of a child for aspiration and swallowing dysfunction is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=see_link\">",
"     \"Aspiration due to swallowing dysfunction in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DROOLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oromotor dysfunction in children with CP often leads to drooling, which is a significant impediment to social acceptance. In one study, the mechanisms of drooling were evaluated in children with CP by measuring intraoral pressure during the suction and propulsion stages of swallowing small amounts of liquid [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/91\">",
"     91",
"    </a>",
"    ]. Drooling was associated with abnormal suction of liquid onto the tongue caused by incomplete lip closure during swallowing, low suction pressure, and prolonged delay between suction and propelling stages.",
"   </p>",
"   <p>",
"    Approaches to improve drooling include medication, behavior therapy, and surgery. Anticholinergic agents, such as benzhexol hydrochloride (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/52/18244?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    hydrochloride),",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/9/34960?source=see_link\">",
"     scopolamine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/4/43078?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    may be effective by decreasing the flow of saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. A flavored liquid formulation of glycopyrrolate (Cuvposa&trade;) has been developed.",
"   </p>",
"   <p>",
"    Another approach is injection of botulinum toxin A (BTX) into the salivary glands. In an open-label clinical trial, drooling severity was measured in 45 children with CP at baseline, after treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/9/34960?source=see_link\">",
"     scopolamine",
"    </a>",
"    , and after submandibular injection with BTX [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/94\">",
"     94",
"    </a>",
"    ]. Drooling was reduced in approximately one-half of patients after both scopolamine and BTX; however fewer and less severe adverse effects were noted with BTX. In another report from the same group, the mean reduction in submandibular flow was significantly greater with BTX injections than with scopolamine therapy (42 and 25 percent respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/95\">",
"     95",
"    </a>",
"    ]. Among responders, the effect of BTX wanes over time, lasting a median of 22 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/96\">",
"     96",
"    </a>",
"    ]. About 25 percent of initial responders still have a clinically significant response at 33 weeks after BTX injection.",
"   </p>",
"   <p>",
"    Surgical treatment of drooling is directed at reducing salivary production. Techniques include repositioning of the submandibular ducts and unilateral ligation of a parotid duct [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Although surgery reduces drooling frequency and severity in 75 to 90 percent of patients, complications such as ranula formation, dry mouth, difficulty with swallowing, and changes in the consistency of oral secretions are common, limiting the acceptance of this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/97,99,100\">",
"     97,99,100",
"    </a>",
"    ]. A case series of patients who were treated with BTX and then surgery suggests that surgery is more consistently and satisfactorily effective in reducing drooling frequency at 8 and 32 week timepoints as compared with BTX [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/100\">",
"     100",
"    </a>",
"    ]. This study is limited by a risk for selection bias because it described only patients who elected to have surgery after undergoing BTX treatment. However, the authors state that the primary motivation for surgery was a desire for a more permanent solution to drooling, rather than primary failure of BTX.",
"   </p>",
"   <p>",
"    Biofeedback techniques and behavior modification have been used to reduce drooling by making swallowing a conscious action. In a study of 12 children with CP, biofeedback training and the use of an auditory signal to cue swallowing increased the rate of swallowing and made swallowing more effective, resulting in significantly decreased drooling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/101\">",
"     101",
"    </a>",
"    ]. A systematic review concluded that there is insufficient evidence to determine if this type of intervention is effective [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drooling improves with age in some patients. Thus, we attempt behavioral and pharmacologic management before considering surgery. This consists of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/4/43078?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    treatment and positive reinforcement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SOCIAL AND PSYCHOLOGICAL SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to any family with a child with a chronic medical condition, social and psychological support is essential. Parents of a child with CP may have chronic grief, as well as guilt, frustration, denial, anger, resentment, and embarrassment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/103\">",
"     103",
"    </a>",
"    ]. They may limit themselves socially and strain relationships with their spouse and other children. Some express dissatisfaction with health care professionals.",
"   </p>",
"   <p>",
"    Information about their child's condition should be provided to parents with honesty and sensitivity beginning with the first encounter. The process of evaluation and management should be described, with the understanding that repetition may be necessary as parents may not assimilate all the information [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. A second opinion should be offered if appropriate.",
"   </p>",
"   <p>",
"    Clinicians should avoid being dogmatic or providing uncertain long-term prognoses. Parents should be given the opportunity to ask questions and express their feelings. They may need to attribute CP to a specific cause, however inappropriate, because the feeling of being victimized by fate is too distressing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/106\">",
"     106",
"    </a>",
"    ]. It is important to attempt to relieve guilt that may result from fantasies of causation. Counseling should be an ongoing process. Parents should be aware that counseling services are always available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Technological support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technological aids provide important support for patients with CP, especially those with severe motor impairment. Equipment such as motorized wheelchairs, switching devices used to activate communication systems, voice-activated computers, and other environmental control systems can improve quality of life by enhancing functional abilities and social interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with CP survive to adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/107-110\">",
"     107-110",
"    </a>",
"    ]. In a regional analysis of children with CP who were born in various regions of the UK between 1980 and 1996, 20-year survival ranged from 87 to 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/109\">",
"     109",
"    </a>",
"    ]. In multivariate analysis, survival was related to severity of impairment, birth weight, and socioeconomic status, with the number of severe impairments having the greatest effect.",
"   </p>",
"   <p>",
"    Survival of adults with CP also depends upon the degree of disability. In one report, life expectancies and predictors of mortality were evaluated in 24,768 affected patients &ge;15 years old who received services in California from 1980 to 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/111\">",
"     111",
"    </a>",
"    ]. Survival in high-functioning adults was similar to the general population. However, life expectancy was substantially reduced in those who lacked basic functional skills of mobility and feeding, to as short as 11 years in the most severely affected. Similar results were shown in a population study from Sweden, in which 60 percent survived to age 19 among children with severe CP (level V of the gross motor function classification system, GMFCS), as compared with 100 percent survival among those with mild gross motor deficits (GMFCS levels I and II) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality rate in patients with severe multiple handicaps is partly affected by the aggressiveness and quality of care. In one study, children with CP who were immobile, had no toilet skills, and required tube feedings typically died by five years of age, and only 20 percent survived to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/112\">",
"     112",
"    </a>",
"    ]. Respiratory disease, often aspiration pneumonia, is the most common cause of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Motor impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of motor impairment is difficult to predict in young children, except at the extremes of mild or severe involvement. In general, prognosis for motor function depends upon the type of CP, rate of motor development, presence of developmental reflexes, intellectual ability, sensory impairment, and emotional-social adjustment. Significant intellectual impairment often, although not always, accompanies severe motor deficit. Patients with CP who walk before age two years typically have normal or borderline normal IQs.",
"   </p>",
"   <p>",
"    Nearly all children with hemiplegic CP will walk, as will many with athetosis or ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/113-117\">",
"     113-117",
"    </a>",
"    ]. The prognosis for walking is poor in children who do not achieve head balance by 20 months, retain primitive reflexes or have no postural reactions by 24 months, or do not crawl by approximately five years of age. The prognosis for walking is good in children who sit by two years and crawl before 30 months of age. Some children who sit between three and four years of age eventually walk, but most require aids or braces or have restricted functional ambulation. In general, children who walk independently do so by approximately three years of age; those who walk only with support may take up to nine years. A child who does not walk by nine years of age is unlikely to ever walk, even with support.",
"   </p>",
"   <p>",
"    In a prospective longitudinal study, 233 children with CP were followed from 12 months to three to 11 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/114\">",
"     114",
"    </a>",
"    ]. Some degree of functional walking was attained by 78.7 percent. The probability of walking was favorable in congenital hemiplegic and ataxic CP and poor in hypotonic CP. However, outcome was quite variable in spastic diplegic, quadriparetic, spastic-athetoid, and athetoid CP. The ability to sit by age two years was a highly reliable predictor of walking. However, more than one-half of those who eventually walked did not sit by two years. Among the latter, suppression of primitive reflex activity between 18 and 24 months predicted eventual walking.",
"   </p>",
"   <p>",
"    In another longitudinal study, 657 children one to 13 years of age with CP were followed serially for four years using validated measures of motor function. Based upon these assessments, curves were created that describe the rate and limit of motor development in children for five levels of severity of motor impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/118\">",
"     118",
"    </a>",
"    ]. These can be used to guide interventions and monitor progress over time.",
"   </p>",
"   <p>",
"    Although these curves provide important prognostic information, parents should understand that considerable variability occurs within each severity group. In addition, functional outcome in CP depends on multiple factors besides motor function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/37/15962/abstract/119\">",
"     119",
"    </a>",
"    ]. These include intelligence, physical function, ability to communicate, and personality attributes. Social (eg, family support) and environmental factors and the availability of specialist medical care play an important role. Adjustment is facilitated by the availability of training, independent or sheltered employment, and counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/8/29825?source=see_link\">",
"       \"Patient information: Cerebral palsy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of the child with cerebral palsy (CP) requires a collaborative approach in which a multidisciplinary team works with the family to maximize the child's social and emotional development, communication, education, nutrition, mobility, and independence in activities of daily living. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spasticity and hyperreflexia can interfere with performance of many physical functions and can lead to contractures. For medical therapy of spasticity, there is stronger evidence to support the use of botulinum toxin than there is for oral antispastic drugs. Surgical approaches may be helpful in severely affected nonambulatory patients with contractures (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Spasticity'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Disorders of the hip, including subluxation, dislocation, and dislocation with degeneration and pain are common complications of spastic CP. Nonambulatory children with bilateral CP are at highest risk for hip dysplasia. Regular radiographic screening allows for early detection and surgical treatment of hip dysplasia and improves outcomes. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Hip disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical therapy is an established part of treatment programs for CP. Although its effectiveness in promoting physical function is uncertain, physical therapy has an important role in supporting and encouraging caretakers to learn how best to handle, toilet, wash and feed their children with CP and to promote posture, mobility, and transfer. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Physical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Constraint-induced movement therapy (CIMT) has been used for children with hemiplegic cerebral palsy in an attempt to promote function of the affected limb through intermittent restraint of the unaffected limb. Electrical stimulation has been used in other children with CP in an effort to increase muscle strength in children with cerebral palsy. Neither of these interventions have proven efficacy. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Constraint therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Electrical stimulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Problems with sucking and swallowing are common in children with CP, and can interfere with nutrition and quality of life, and cause complications such as aspiration pneumonia. Gastrostomy feeding may improve nutrition in severely affected children, and it reduces, but does not eliminate, aspiration. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Feeding disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.lifeexpectancy.org/articles/newgrowthcharts.shtml\">",
"       Growth charts specific for children with CP",
"      </a>",
"      have been developed, and these define a weight threshold below which morbidity and mortality is increased. Patients with weights below this threshold should undergo a nutritional evaluation, including evaluation of caloric intake and exploration of alternative explanations for low body weight, such as familial short stature. If under-nutrition is confirmed, we suggest concerted efforts to boost nutrition through oral supplements or enteral feeds (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6045874\">",
"       'Evaluation and growth charts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oromotor dysfunction in children with CP can cause drooling, which is a barrier to social acceptance. Medical and behavioral interventions are helpful in many patients, and the symptom often improves as the child grows older. Surgical intervention is effective for refractory cases. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Drooling'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis for survival and motor function in children with CP is highly variable, and depends on the severity and type of the CP syndrome. Nearly all children with hemiplegic CP will walk. The prognosis for walking is poor in children who do not achieve head balance by 20 months, retain primitive reflexes, or have no postural reactions by 24 months. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bagnato SJ, Campbell TF. Comprehensive neurodevelopmental evaluation of children with brain insults. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ranier JC (Eds), Raven, New York 1992. p.27.",
"    </li>",
"    <li>",
"     Zuromski ES. The management of mental retardation. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ramer JC (Eds), Raven, New York 1992. p.119.",
"    </li>",
"    <li>",
"     Finnie N. Handling the Young Cerebral Palsied Child at Home, Heinemann, London 1974.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/4\">",
"      Landau WM. Clinical neuromythology II. Parables of palsy pills and PT pedagogy: a spastic dialectic. Neurology 1988; 38:1496.",
"     </a>",
"    </li>",
"    <li>",
"     Glenn MB, Whyte J. The Practical Management of Spasticity in Children and Adults, Lea &amp; Fegiber, Philadelphia 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/6\">",
"      Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society, Delgado MR, Hirtz D, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010; 74:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/7\">",
"      Petersen MC, Palmer FB. Advances in prevention and treatment of cerebral palsy. Ment Retard Dev Disabil Res Rev 2001; 7:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/8\">",
"      Snow BJ, Tsui JK, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/9\">",
"      Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/10\">",
"      Koman LA, Mooney JF 3rd, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994; 14:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/11\">",
"      Dursun N, Dursun E, Alican D. The role of botulinum toxin a in the management of lower limb spasticity in patients with cerebral palsy. Int J Clin Pract 2002; 56:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/12\">",
"      Baker R, Jasinski M, Maciag-Tymecka I, et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002; 44:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/13\">",
"      Polak F, Morton R, Ward C, et al. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2002; 44:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/14\">",
"      Cardoso ES, Rodrigues BM, Barroso M, et al. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neurol 2006; 34:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/15\">",
"      Tedroff K, L&ouml;wing K, Haglund-Akerlind Y, et al. Botulinum toxin A treatment in toddlers with cerebral palsy. Acta Paediatr 2010; 99:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/16\">",
"      Hoare BJ, Wallen MA, Imms C, et al. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010; :CD003469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/17\">",
"      Bleck EE. Cerebral palsy hip deformities: is there a consensus? II. Botulinum toxin A: a clinical experiment. J Pediatr Orthop 1994; 14:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/18\">",
"      Neville B. Botulinum toxin in the cerebral palsies. BMJ 1994; 309:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/19\">",
"      Tedroff K, Granath F, Forssberg H, Haglund-Akerlind Y. Long-term effects of botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 2009; 51:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/20\">",
"      Bjornson K, Hays R, Graubert C, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics 2007; 120:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/21\">",
"      Patrick JH, Roberts AP, Cole GF. Therapeutic choices in the locomotor management of the child with cerebral palsy--more luck than judgement? Arch Dis Child 2001; 85:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/22\">",
"      Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/23\">",
"      Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997; 6:S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/24\">",
"      Moore AP, Ade-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008; 71:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/25\">",
"      Russman BS, Tilton A, Gormley ME Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl 1997; 6:S181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/26\">",
"      Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/27\">",
"      Koman LA, Mooney JF 3rd, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000; 20:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/28\">",
"      Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001; 108:1062.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Information for healthcare professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm (Accessed on August 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/30\">",
"      Montan&eacute; E, Vallano A, Laporte JR. Oral antispastic drugs in nonprogressive neurologic diseases: a systematic review. Neurology 2004; 63:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/31\">",
"      Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977; 5:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/32\">",
"      Haslam RH, Walcher JR, Lietman PS, et al. Dantrolene sodium in children with spasticity. Arch Phys Med Rehabil 1974; 55:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/33\">",
"      Joynt RL, Leonard JA Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980; 22:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/34\">",
"      Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981; 304:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/35\">",
"      Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977; 72:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/36\">",
"      Mathew A, Mathew MC, Thomas M, Antonisamy B. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr 2005; 51:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/37\">",
"      Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol 1985; 17:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/38\">",
"      Scheinberg A, Hall K, Lam LT, O'Flaherty S. Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. J Paediatr Child Health 2006; 42:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/39\">",
"      Terrence CF, Fromm GH. Complications of baclofen withdrawal. Arch Neurol 1981; 38:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/40\">",
"      Motta F, Buonaguro V, Stignani C. The use of intrathecal baclofen pump implants in children and adolescents: safety and complications in 200 consecutive cases. J Neurosurg 2007; 107:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/41\">",
"      Pin TW, McCartney L, Lewis J, Waugh MC. Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. Dev Med Child Neurol 2011; 53:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/42\">",
"      Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008; 22:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/43\">",
"      Albright AL. Baclofen in the treatment of cerebral palsy. J Child Neurol 1996; 11:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/44\">",
"      Albright AL, Cervi A, Singletary J. Intrathecal baclofen for spasticity in cerebral palsy. JAMA 1991; 265:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/45\">",
"      Albright AL, Gilmartin R, Swift D, et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 2003; 98:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/46\">",
"      Ramstad K, Jahnsen R, Lofterod B, Skjeldal OH. Continuous intrathecal baclofen therapy in children with cerebral palsy - when does improvement emerge? Acta Paediatr 2010; 99:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/47\">",
"      Morton RE, Gray N, Vloeberghs M. Controlled study of the effects of continuous intrathecal baclofen infusion in non-ambulant children with cerebral palsy. Dev Med Child Neurol 2011; 53:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/48\">",
"      McLaughlin J, Bjornson K, Temkin N, et al. Selective dorsal rhizotomy: meta-analysis of three randomized controlled trials. Dev Med Child Neurol 2002; 44:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/49\">",
"      Steinbok P, Reiner AM, Beauchamp R, et al. A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy. Dev Med Child Neurol 1997; 39:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/50\">",
"      Wright FV, Sheil EM, Drake JM, et al. Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled tria. Dev Med Child Neurol 1998; 40:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/51\">",
"      McLaughlin JF, Bjornson KF, Astley SJ, et al. Selective dorsal rhizotomy: efficacy and safety in an investigator-masked randomized clinical trial. Dev Med Child Neurol 1998; 40:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/52\">",
"      Mittal S, Farmer JP, Al-Atassi B, et al. Long-term functional outcome after selective posterior rhizotomy. J Neurosurg 2002; 97:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/53\">",
"      Cole GF, Farmer SE, Roberts A, et al. Selective dorsal rhizotomy for children with cerebral palsy: the Oswestry experience. Arch Dis Child 2007; 92:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/54\">",
"      Speelman D, van Manen J. Cerebral palsy and stereotactic neurosurgery: long term results. J Neurol Neurosurg Psychiatry 1989; 52:23.",
"     </a>",
"    </li>",
"    <li>",
"     Bieck EE. Orthopaedic Management in Cerebral Palsy, Mackeith, Oxford 1987.",
"    </li>",
"    <li>",
"     Koop SE. Orthopedic aspects of static encephalopathies. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ramer JC (Eds), Raven, New York 1992. p.95.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/57\">",
"      Cornell MS. The hip in cerebral palsy. Dev Med Child Neurol 1995; 37:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/58\">",
"      Bleck EE. Management of the lower extremities in children who have cerebral palsy. J Bone Joint Surg Am 1990; 72:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/59\">",
"      Sutherland DH, Davids JR. Common gait abnormalities of the knee in cerebral palsy. Clin Orthop Relat Res 1993; :139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/60\">",
"      Baddar A, Granata K, Damiano DL, et al. Ankle and knee coupling in patients with spastic diplegia: effects of gastrocnemius-soleus lengthening. J Bone Joint Surg Am 2002; 84-A:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/61\">",
"      Abel MF, Damiano DL, Pannunzio M, Bush J. Muscle-tendon surgery in diplegic cerebral palsy: functional and mechanical changes. J Pediatr Orthop 1999; 19:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/62\">",
"      Flynn JM, Miller F. Management of hip disorders in patients with cerebral palsy. J Am Acad Orthop Surg 2002; 10:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/63\">",
"      Dobson F, Boyd RN, Parrott J, et al. Hip surveillance in children with cerebral palsy. Impact on the surgical management of spastic hip disease. J Bone Joint Surg Br 2002; 84:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/64\">",
"      Pountney T, Mandy A, Green E, Gard P. Management of hip dislocation with postural management. Child Care Health Dev 2002; 28:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/65\">",
"      Palmer FB, Shapiro BK, Wachtel RC, et al. The effects of physical therapy on cerebral palsy. A controlled trial in infants with spastic diplegia. N Engl J Med 1988; 318:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/66\">",
"      Cherng RJ, Liu CF, Lau TW, Hong RB. Effect of treadmill training with body weight support on gait and gross motor function in children with spastic cerebral palsy. Am J Phys Med Rehabil 2007; 86:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/67\">",
"      Valentin-Gudiol M, Mattern-Baxter K, Girabent-Farr&eacute;s M, et al. Treadmill interventions with partial body weight support in children under six years of age at risk of neuromotor delay. Cochrane Database Syst Rev 2011; :CD009242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/68\">",
"      Hoare BJ, Wasiak J, Imms C, Carey L. Constraint-induced movement therapy in the treatment of the upper limb in children with hemiplegic cerebral palsy. Cochrane Database Syst Rev 2007; :CD004149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/69\">",
"      Eliasson AC, Krumlinde-sundholm L, Shaw K, Wang C. Effects of constraint-induced movement therapy in young children with hemiplegic cerebral palsy: an adapted model. Dev Med Child Neurol 2005; 47:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/70\">",
"      Sung IY, Ryu JS, Pyun SB, et al. Efficacy of forced-use therapy in hemiplegic cerebral palsy. Arch Phys Med Rehabil 2005; 86:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/71\">",
"      Kerr C, McDowell B, Cosgrove A, et al. Electrical stimulation in cerebral palsy: a randomized controlled trial. Dev Med Child Neurol 2006; 48:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/72\">",
"      Kerr C, McDowell B, McDonough S. Electrical stimulation in cerebral palsy: a review of effects on strength and motor function. Dev Med Child Neurol 2004; 46:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/73\">",
"      van der Linden ML, Hazlewood ME, Aitchison AM, et al. Electrical stimulation of gluteus maximus in children with cerebral palsy: effects on gait characteristics and muscle strength. Dev Med Child Neurol 2003; 45:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/74\">",
"      Collet JP, Vanasse M, Marois P, et al. Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. HBO-CP Research Group. Lancet 2001; 357:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/75\">",
"      Lacey DJ, Stolfi A, Pilati LE. Effects of hyperbaric oxygen on motor function in children with cerebral palsy. Ann Neurol 2012; 72:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/76\">",
"      Dahl M, Thommessen M, Rasmussen M, Selberg T. Feeding and nutritional characteristics in children with moderate or severe cerebral palsy. Acta Paediatr 1996; 85:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/77\">",
"      Reilly S, Skuse D, Poblete X. Prevalence of feeding problems and oral motor dysfunction in children with cerebral palsy: a community survey. J Pediatr 1996; 129:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/78\">",
"      Andrew MJ, Parr JR, Sullivan PB. Feeding difficulties in children with cerebral palsy. Arch Dis Child Educ Pract Ed 2012; 97:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/79\">",
"      Sullivan PB, Lambert B, Rose M, et al. Prevalence and severity of feeding and nutritional problems in children with neurological impairment: Oxford Feeding Study. Dev Med Child Neurol 2000; 42:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/80\">",
"      Fung EB, Samson-Fang L, Stallings VA, et al. Feeding dysfunction is associated with poor growth and health status in children with cerebral palsy. J Am Diet Assoc 2002; 102:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/81\">",
"      Erasmus CE, van Hulst K, Rotteveel JJ, et al. Clinical practice: swallowing problems in cerebral palsy. Eur J Pediatr 2012; 171:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/82\">",
"      Samson-Fang LJ, Stevenson RD. Identification of malnutrition in children with cerebral palsy: poor performance of weight-for-height centiles. Dev Med Child Neurol 2000; 42:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/83\">",
"      Stevenson RD. Use of segmental measures to estimate stature in children with cerebral palsy. Arch Pediatr Adolesc Med 1995; 149:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/84\">",
"      Brooks J, Day S, Shavelle R, Strauss D. Low weight, morbidity, and mortality in children with cerebral palsy: new clinical growth charts. Pediatrics 2011; 128:e299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/85\">",
"      Sullivan PB, Juszczak E, Bachlet AM, et al. Gastrostomy tube feeding in children with cerebral palsy: a prospective, longitudinal study. Dev Med Child Neurol 2005; 47:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/86\">",
"      Brant CQ, Stanich P, Ferrari AP Jr. Improvement of children's nutritional status after enteral feeding by PEG: an interim report. Gastrointest Endosc 1999; 50:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/87\">",
"      Kong CK, Wong HS. Weight-for-height values and limb anthropometric composition of tube-fed children with quadriplegic cerebral palsy. Pediatrics 2005; 116:e839.",
"     </a>",
"    </li>",
"    <li>",
"     Ferluga ED, Archer KR, Sathe NA, et al. Interventions for Feeding and Nutrition in Cerebral Palsy. Comp Effectiveness Review, US Department of Health and Human Services; Agency for Healthcare Research and Quality, Rockville, MD 2013.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/89\">",
"      Smith SW, Camfield C, Camfield P. Living with cerebral palsy and tube feeding: A population-based follow-up study. J Pediatr 1999; 135:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/90\">",
"      Gisel E. Gastrostomy feeding in cerebral palsy: too much of a good thing? Dev Med Child Neurol 2006; 48:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/91\">",
"      Lespargot A, Langevin MF, Muller S, Guillemont S. Swallowing disturbances associated with drooling in cerebral-palsied children. Dev Med Child Neurol 1993; 35:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/92\">",
"      Reddihough D, Johnson H, Staples M, et al. Use of benzhexol hydrochloride to control drooling of children with cerebral palsy. Dev Med Child Neurol 1990; 32:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/93\">",
"      Siegel LK, Klingbeil MA. Control of drooling with transdermal scopolamine in a child with cerebral palsy. Dev Med Child Neurol 1991; 33:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/94\">",
"      Jongerius PH, van den Hoogen FJ, van Limbeek J, et al. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial. Pediatrics 2004; 114:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/95\">",
"      Jongerius PH, Rotteveel JJ, van Limbeek J, et al. Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology 2004; 63:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/96\">",
"      Scheffer AR, Erasmus C, van Hulst K, et al. Efficacy and duration of botulinum toxin treatment for drooling in 131 children. Arch Otolaryngol Head Neck Surg 2010; 136:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/97\">",
"      Webb K, Reddihough DS, Johnson H, et al. Long-term outcome of saliva-control surgery. Dev Med Child Neurol 1995; 37:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/98\">",
"      Sellars SL. Surgery of sialorrhoea. J Laryngol Otol 1985; 99:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/99\">",
"      Greensmith AL, Johnstone BR, Reid SM, et al. Prospective analysis of the outcome of surgical management of drooling in the pediatric population: a 10-year experience. Plast Reconstr Surg 2005; 116:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/100\">",
"      Scheffer AR, Erasmus C, VAN Hulst K, et al. Botulinum toxin versus submandibular duct relocation for severe drooling. Dev Med Child Neurol 2010; 52:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/101\">",
"      Koheil R, Sochaniwskyj AE, Bablich K, et al. Biofeedback techniques and behaviour modification in the conservative remediation of drooling by children with cerebral palsy. Dev Med Child Neurol 1987; 29:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/102\">",
"      Arvedson J, Clark H, Lazarus C, et al. The effects of oral-motor exercises on swallowing in children: an evidence-based systematic review. Dev Med Child Neurol 2010; 52:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/103\">",
"      Olshanksy S. Chronic sorrow: a response to having a mentally defective child. Soc Casework 1962; 43:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/104\">",
"      Taylor DC. Counselling the parents of handicapped children. Br Med J (Clin Res Ed) 1982; 284:1027.",
"     </a>",
"    </li>",
"    <li>",
"     Barowsky El. Communicating information. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ranier JC (Eds), Raven, New York 1992. p.111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/106\">",
"      Bentovim A. Emotional disturbances of handicapped pre-school children and their families--attitudes to the child. Br Med J 1972; 3:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/107\">",
"      Crichton JU, Mackinnon M, White CP. The life-expectancy of persons with cerebral palsy. Dev Med Child Neurol 1995; 37:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/108\">",
"      Hutton JL, Cooke T, Pharoah PO. Life expectancy in children with cerebral palsy. BMJ 1994; 309:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/109\">",
"      Hemming K, Hutton JL, Colver A, Platt MJ. Regional variation in survival of people with cerebral palsy in the United Kingdom. Pediatrics 2005; 116:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/110\">",
"      Westbom L, Bergstrand L, Wagner P, Nordmark E. Survival at 19 years of age in a total population of children and young people with cerebral palsy. Dev Med Child Neurol 2011; 53:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/111\">",
"      Strauss D, Shavelle R. Life expectancy of adults with cerebral palsy. Dev Med Child Neurol 1998; 40:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/112\">",
"      Eyman RK, Grossman HJ, Chaney RH, Call TL. Survival of profoundly disabled people with severe mental retardation. Am J Dis Child 1993; 147:329.",
"     </a>",
"    </li>",
"    <li>",
"     Crothers B, Paine S. The Natural History of Cerebral Palsy, Harvard University Press, Cambridge 1959.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/114\">",
"      Molnar GE, Gordon SU. Cerebral palsy: predictive value of selected clinical signs for early prognostication of motor function. Arch Phys Med Rehabil 1976; 57:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/115\">",
"      Bleck EE. Locomotor prognosis in cerebral palsy. Dev Med Child Neurol 1975; 17:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/116\">",
"      da Paz J&uacute;nior AC, Burnett SM, Braga LW. Walking prognosis in cerebral palsy: a 22-year retrospective analysis. Dev Med Child Neurol 1994; 36:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/117\">",
"      Sala DA, Grant AD. Prognosis for ambulation in cerebral palsy. Dev Med Child Neurol 1995; 37:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/118\">",
"      Rosenbaum PL, Walter SD, Hanna SE, et al. Prognosis for gross motor function in cerebral palsy: creation of motor development curves. JAMA 2002; 288:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/37/15962/abstract/119\">",
"      Kinsman SL. Predicting gross motor function in cerebral palsy. JAMA 2002; 288:1399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6176 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15962=[""].join("\n");
var outline_f15_37_15962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT GOALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Multidisciplinary team",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPASTICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Botulinum toxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oral antispastic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Dantrolene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Baclofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intrathecal baclofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Selective dorsal rhizotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Stereotactic encephalotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ORTHOPEDIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Muscle-tendon surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hip disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PHYSICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49061679\">",
"      OTHER INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Constraint therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Electrical stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12930776\">",
"      Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FEEDING DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6045874\">",
"      Evaluation and growth charts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DROOLING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SOCIAL AND PSYCHOLOGICAL SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Technological support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Motor impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6176\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6176|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/24/7563\" title=\"table 1\">",
"      Priorities for management of cerebral palsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38632?source=related_link\">",
"      Aspiration due to swallowing dysfunction in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4104?source=related_link\">",
"      Diagnosis and classification of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=related_link\">",
"      Enteral nutrition in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/8/29825?source=related_link\">",
"      Patient information: Cerebral palsy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_37_15963="Fitzpatrick skin phototypes";
var content_f15_37_15963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fitzpatrick skin phototypes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Skin type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Unexposed skin color",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reaction to sun exposure*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        White",
"       </td>",
"       <td>",
"        Always burns, never tans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        White",
"       </td>",
"       <td>",
"        Always burns, minimal tan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        White to olive",
"       </td>",
"       <td>",
"        Burns minimally, gradually tans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Light brown",
"       </td>",
"       <td>",
"        Burns minimally, tans well",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V",
"       </td>",
"       <td>",
"        Brown",
"       </td>",
"       <td>",
"        Very rarely burns, tans profusely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VI",
"       </td>",
"       <td>",
"        Dark brown to black",
"       </td>",
"       <td>",
"        Never burns, tans deeply",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: Slight variations on the definitions of the phototypes appear in the literature.",
"    <div class=\"footnotes\">",
"     * After the first one hour of sun exposure on untanned skin on the first day of spring.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15963=[""].join("\n");
var outline_f15_37_15963=null;
var title_f15_37_15964="PCN all hx given ceph";
var content_f15_37_15964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of cephalosporin challenges in patients with histories of penicillin allergy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Reference",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Cephalosporin reaction rate",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Cephalosporins administered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        History of pcn allergy (percent)",
"       </td>",
"       <td class=\"subtitle2\">",
"        No history of pcn allergy (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dash CH (1975)",
"       </td>",
"       <td>",
"        25 of 324 (7.7)",
"       </td>",
"       <td>",
"        140 of 17,216 (0.8)",
"       </td>",
"       <td>",
"        Cephalexin and cephaloridine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Petz LD (1978)",
"       </td>",
"       <td>",
"        57 of 701 (8.1)",
"       </td>",
"       <td>",
"        285 of 15,007 (1.9)",
"       </td>",
"       <td>",
"        Cephalexin, cephaloridine, cephalothin, cefazolin, and cefamandole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goodman EJ (2001)",
"       </td>",
"       <td>",
"        1 of 300 (0.3)",
"       </td>",
"       <td>",
"        1 of 2431 (0.04)",
"       </td>",
"       <td>",
"        Cefazolin (in all but one patient)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Daulat SB (2004)",
"       </td>",
"       <td rowspan=\"3\">",
"        1 of 606 (0.17)",
"       </td>",
"       <td rowspan=\"3\">",
"        15 of 22,664 (0.07)",
"       </td>",
"       <td>",
"        1st generation (42 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2nd generation (21 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3rd/4th generations (37 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Fonacier L (2005)",
"       </td>",
"       <td rowspan=\"4\">",
"        7 of 83 (8.4)",
"       </td>",
"       <td rowspan=\"4\">",
"        Not reported",
"       </td>",
"       <td>",
"        1st generation (59 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2nd generation (8.4 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3rd generation (25 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4th generation (7 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MacPherson RD (2006)",
"       </td>",
"       <td>",
"        0 of 84 (0)",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        Cefazolin, cefotetan, ceftriaxone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of studies of cephalosporin challenges in patients with a history of penicillin (pcn) allergy without preceding penicillin allergy testing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15964=[""].join("\n");
var outline_f15_37_15964=null;
var title_f15_37_15965="Annual bariatric procedures US";
var content_f15_37_15965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Estimated number of bariatric operations performed in the United States, 1992-2003",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 276px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the American Society for Bariatric Surgery.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15965=[""].join("\n");
var outline_f15_37_15965=null;
var title_f15_37_15966="Contents: Hospital rheumatology";
var content_f15_37_15966=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?2/63/3070\">",
"       Hospital Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital rheumatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital rheumatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/33/10777\">",
"           Causes of rhabdomyolysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/23/37241\">",
"           Classification of and approach to the vasculitides in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/3/44087\">",
"           Classification of scleroderma disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/19/13624\">",
"           Clinical features and diagnosis of Takayasu arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/46/13033\">",
"           Clinical features of rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/49/4890\">",
"           Clinical manifestations and diagnosis of gout",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/26/9641\">",
"           Clinical manifestations and diagnosis of polyarteritis nodosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/55/32632\">",
"           Clinical manifestations and diagnosis of rhabdomyolysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/13/20697\">",
"           Clinical manifestations and diagnosis of rheumatoid vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/57/22423\">",
"           Clinical manifestations of vasculitic neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/39/1658\">",
"           Complications of total hip arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/32/16902\">",
"           Complications of total knee arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/44/31433\">",
"           Coronary artery disease in rheumatoid arthritis: Diagnostic and therapeutic implications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/13/28889\">",
"           Coronary heart disease in systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/61/31703\">",
"           Determinants of glucocorticoid dosing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/53/16215\">",
"           Diagnosis and treatment of vasculitic neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/50/34599\">",
"           Diagnosis of giant cell (temporal) arteritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/32/28168\">",
"           Drug-induced lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6856\">",
"           Drug-induced myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/37/22103\">",
"           Glucocorticoid withdrawal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/31/18937\">",
"           Hip fractures in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/57/30614\">",
"           Hypersensitivity vasculitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/57/28564\">",
"           Joint aspiration or injection in adults: Complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/52/23368\">",
"           Joint aspiration or injection in adults: Technique and indications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/31/28148\">",
"           Joint aspiration: The dry tap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/35/15929\">",
"           Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/60/11210\">",
"           Pulmonary manifestations of systemic lupus erythematosus in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/55/10106\">",
"           Total hip arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/6/17514\">",
"           Total knee arthroplasty",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/29/28119\">",
"           Treatment and prognosis of polyarteritis nodosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/21/13658\">",
"           Treatment of acute low back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/19/22841\">",
"           Treatment of rheumatoid vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/60/3015\">",
"           Treatment of Takayasu arteritis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-9A15C4D5FE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_37_15966=[""].join("\n");
var outline_f15_37_15966=null;
var title_f15_37_15967="Countercurrent mechanism urea";
var content_f15_37_15967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Role of urea in the countercurrent mechanism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mechanism by which urea achieves high concentrations in the medullary interstitium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_37_15967=[""].join("\n");
var outline_f15_37_15967=null;
